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ABSTRACT OF THE DISSERTATION
In Vivo Mechanisms of Natural Killer Cell Tolerance
by
Michael David Bern
Doctor of Philosophy in Biology and Biomedical Sciences
Immunology
Washington University in St. Louis, 2020
Professor Wayne M. Yokoyama, Chair

Natural killer (NK) cells are cytotoxic innate immune cells that provide protection from
pathogens and tumors. To carry out these functions, NK cells must distinguish between healthy
and unhealthy self-cells. Inability to recognize stressed cells would lead to a failure of NK-cell
immunity whereas inability to identify healthy cells could lead to NK-cell autoimmunity. It
remains unclear, however, how NK cells are able to distinguish healthy and unhealthy self-cells
with a limited repertoire of germline-encoded receptors. The “missing-self” hypothesis proposes
that NK cells identify stressed cells by their reduced expression of MHC class I (MHC-I) that is
almost ubiquitously expressed as self. NK cells express inhibitory Ly49 receptors that bind to
MHC-I and inhibit NK cells from killing healthy cells, and downregulation of MHC-I on
stressed cells leads to loss of inhibition and killing by missing-self recognition. The importance
of Ly49 receptors and MHC-I for maintaining NK-cell self-tolerance, however, has only been
suggested by in vitro experiments and correlative in vivo experiments. Here we generated a
mouse with a mutation in the immunoreceptor tyrosine-based inhibitory motif of Ly49A and
another mouse with an allele of the gene for beta2-microglobulin containing loxP sites (B2mfl) to
vii

directly test the roles of Ly49s and MHC-I in NK cell self-tolerance in vivo. Loss of inhibitory
signaling through a mutant Ly49 or global MHC-I downregulation induced changes in NK-cell
responsiveness or inhibitory receptor expression that maintained NK-cell self-tolerance. In
contrast, downregulation of MHC-I on CD4+ T cells, led to a subtle loss of CD4+ T cells, but NK
cells remained tolerant to a substantial population of MHC-I-deficient CD4+ T cells without
altering their responsiveness or receptor repertoire. In this setting, infection with murine
cytomegalovirus or treatment with a toll-like receptor agonist induced NK cell-mediated
rejection of MHC-I-deficient CD4+ T cells. These results show that loss of inhibitory signaling to
NK cells in vivo can induce tolerance or rejection of missing-self in different contexts and that
inflammation promotes missing-self reactivity.
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Chapter 1: Introduction
1.1 Natural killer cells
1.1.1 NK cell definition and function
Innate immune cells are defined by their ability to recognize pathogens or infected cells
through germline-encoded receptors (Janeway and Medzhitov, 2002). This is in contrast to
adaptive immune cells, such as B and T cells, that require gene rearrangement to form antigenspecific receptors (Janeway and Medzhitov, 2002). Gene rearrangement generates a much larger
repertoire of antigen receptors than can be germline-encoded in the genome, which provides
adaptive immune cells the ability to recognize a substantially broader array of non-self molecules
than innate immune cells (Vivier et al., 2011). How the innate immune system is able to
discriminate self from non-self utilizing a narrow repertoire of germline-encoded specificities is
an active area of investigation. Because of the large repertoire of adaptive immune receptors, T
and B cells expressing a particular antigen receptor are rare and must clonally expand over a
period of days prior to providing protective immunity (Janeway and Medzhitov, 2002). In
contrast, innate immune cells presumably do not require clonal expansion and are able to
respond rapidly to infections, which in part functions to protect the host long enough for the
adaptive immune system to respond (Janeway and Medzhitov, 2002).
Natural killer (NK) cells are innate immune cells that were first identified as non-T non-B
lymphocytes from the spleens of naïve mice that could lyse the YAC-1 Moloney leukemia virus
(MLV)-induced tumor cell line in vitro (Kiessling et al., 1975a; Kiessling et al., 1975b). NK cells
were labeled as “natural” killers because cytotoxicity was observed without prior immunization
1

in contrast to T cell-mediated killing, which requires immunization to prime antigen-specific
naïve T cells and increase their frequency by clonal expansion (Williams and Bevan, 2007).
Natural killer activity was also observed in lymphocytes from the peripheral blood of humans
when incubated with the K-562 myeloid leukemia cell line (Jondal and Pross, 1975). NK cells
are categorized as innate immune cells due to this ability to kill target cells without prior
sensitization (Vivier et al., 2011) and because functional NK cells develop in SCID mice
(Dorshkind et al., 1985) and RAG-deficient mice (Shinkai et al., 1992) that lack the ability to
rearrange antigen receptor gene segments, which suggests that NK cells utilize germline-encoded
receptors.
Consistent with their initially described ability to lyse tumor cells in vitro, NK cells
protect mice from transplanted and spontaneous tumors in vivo (Guerra et al., 2008; Karre et al.,
1986; Talmadge et al., 1980). NK cells also reject MHC-mismatched bone marrow transplants
(Cudkowicz and Bennett, 1971; Murphy et al., 1987a) and protect mice from infections with
intracellular pathogens, such as murine cytomegalovirus (MCMV) (Bukowski et al., 1983). NK
cells provide immunity in vivo through both direct cytotoxicity and the production of cytokines,
such as interferon-γ (IFN-γ) (Long et al., 2013; Presti et al., 1998). The mechanism of NK cellmediated cytotoxicity is thought to utilize granzyme B (Shresta et al., 1995) and perforin (Lowin
et al., 1994) similar to CD8+ T cells (Long et al., 2013) based on in vitro assays. As such,
perforin- and granzyme B-deficient mice are susceptible to MCMV (Fehniger et al., 2007).
However, NK cell-mediated rejection of mismatched bone marrow grafts is independent of
perforin (Baker et al., 1995; Bennett et al., 1998), suggesting that differences may exist between
the mechanisms of action of NK cells in vitro and in vivo.

2

Notably, the originally described “natural” cytotoxicity by fresh NK cells in vitro was
restricted to a small number of tumor cell targets (Kiessling et al., 1975b; Rosenstein et al., 1984)
and was ineffective against most fresh tumor cells from both mice (Kiessling et al., 1975b) and
humans (Grimm et al., 1982; Vose and Moore, 1980). Subsequent studies showed that NK cells
could kill a substantially broader array of target cells in vitro including fresh tumor cells after
culture in IL-2 to generate “lymphokine-activated killer” (LAK) cells (Grimm et al., 1982;
Rosenstein et al., 1984), by treatment with interferon (Djeu et al., 1979; Vose and Moore, 1980),
or by pretreating mice with poly(I:C) (Djeu et al., 1979; Liao et al., 1991). Similarly, NK cellmediated cytotoxic control of MCMV requires priming of NK cells by type I interferon and IL12 (Parikh et al., 2015), which suggests that NK cells require cytokine activation to provide
protective immunity to viral infection. In contrast, however, NK cells reject tumor cells (Kärre et
al., 1986) and MHC-mismatched bone marrow grafts (Cudkowicz and Bennett, 1971; Murphy et
al., 1987a) in vivo without pre-treating mice with inflammatory stimuli. As a result, it still
remains unclear if NK cell-mediated protective immunity is truly “natural” or requires prior
activation in vivo.

1.1.2 NK cell development
NK cells were initially characterized as lymphocytes based on cellular morphology
(Kiessling et al., 1975a). Consistent with NK cells belonging to the lymphoid lineage with T and
B cells, mice lacking the transcription factor Ikaros lack all three of these cell populations
(Georgopoulos et al., 1994). Additionally, a common lymphoid progenitor (CLP) in the mouse
bone marrow gives rise to T, B, and NK cells (Kondo et al., 1997). NK cells, however, develop
in athymic nude mice that cannot support T cell development (Kiessling et al., 1975a) as well as
SCID mice and RAG-deficient mice as mentioned previously (Dorshkind et al., 1985; Shinkai et
3

al., 1992). Moreover, bone marrow progenitor populations have been identified that give rise to
NK cells but not T or B cells, which separates NK cells as a distinct lineage from T and B cells
within the lymphoid lineage (Fathman et al., 2011; Rosmaraki et al., 2001).
After release from the bone marrow, NK cells continue to progress through stages of
“maturation” that are delineated based on expression of CD11b and CD27 (Hayakawa and
Smyth, 2006; Kim et al., 2002). NK cells progress from immature CD11b- CD27- cells to
CD11b- CD27+ to CD11b+ CD27+ to terminally mature CD11b+ CD27- (Chiossone et al., 2009).
Mature NK cells exhibit increased or decreased functionality compared to immature NK cells
depending on the particular study (Hayakawa and Smyth, 2006; Joncker et al., 2010; Kim et al.,
2002). However, knockout mice that exhibit blocks in NK cell maturation, also exhibit defects in
NK cell-mediated tumor rejection (Gordon et al., 2012; van Helden et al., 2015; Werneck et al.,
2008). As a result, NK cell maturation status is often used as metric of NK cell functionality.
Notably, however, the stages of NK cell development and maturation do not correspond to any
known steps of positive or negative selection such as those that establish central tolerance during
T cell development in the thymus (Xing and Hogquist, 2012).

1.2 The “missing-self” hypothesis
1.2.1 NK cells recognize “missing-self”
MHC-I is a nearly ubiquitously expressed cell surface protein complex composed of a
polymorphic heavy chain (H-2Kb or H-2Db in C57BL/6 mice) and beta2-microglobulin (B2m)
that presents intracellular peptides to cytotoxic CD8+ T cells (Neefjes et al., 2011). Intracellular
pathogens and transformed cells evolve strategies to downregulate MHC-I to evade clearance by
MHC-I-restricted cytotoxic T cells (Malmberg et al., 2017). In response, NK cells are thought to
4

recognize and kill target cells that downregulate MHC-I through “missing-self” recognition to
complement cytotoxic T cell-mediated immunity (Kärre et al., 1986; Ljunggren and Karre,
1990). As a result, the missing-self hypothesis provides a theoretical framework for how NK
cells can recognize stressed cells with a limited number of germline-encoded receptors.
Initial evidence for the missing-self hypothesis came from experiments showing that NK
cells reject the MHC-I-deficient tumor cell line RMA/s but not the MHC-I-positive tumor cell
line RMA after adoptive transfer in vivo (Kärre et al., 1986). Additionally, NK cells from
poly(I:C)-treated mice kill RMA/s but not RMA cells in vitro (Kärre et al., 1986). Subsequent
studies showed that NK cells from H-2Dd-transgenic (D8) mice reject non-transgenic bone
marrow, which suggested that missing-self recognition also explained the previously recognized
ability of NK cells reject MHC-mismatched bone marrow grafts (Murphy et al., 1987b; Ohlen et
al., 1989).
Definitive evidence for the missing-self hypothesis, however, came only after the
development of the B2m knockout (B2m-/-) mouse that lacks surface MHC-I expression
altogether (Koller et al., 1990; Zijlstra et al., 1990). NK cells from wild type (WT) mice reject
adoptively transferred B2m-/- bone marrow and splenocytes in vivo (Bix et al., 1991; Oberg et al.,
2004). Additionally, NK cells from mice pre-treated with poly(I:C) or tilorone directly kill
concanavalin A (ConA)-induced B2m-/- T cell blasts in vitro (Hoglund et al., 1991; Liao et al.,
1991). For unclear reasons, however, B2m-/- mice do not exhibit NK cell-mediated autoimmunity
(Liao et al., 1991). As a result, evidence for the missing-self hypothesis is restricted to in vitro
experiments with pre-activated NK cells and in vivo experiments using adoptively transferred
MHC-I-deficient targets.
5

1.2.2 Inhibitory receptors mediate “missing-self” recognition
Inhibitory Ly49 receptors are thought to be the missing-self receptors in mice. Inhibitory
Ly49s directly bind to MHC-I to inhibit killing of healthy cells that express normal levels of selfMHC-I (Karlhofer et al., 1992). As a result, downregulation of MHC-I on target cells is thought
to induce NK cell activation and killing through a loss of inhibitory Ly49 signaling (Karlhofer et
al., 1992). Humans express a structurally divergent family of receptors called the killer
immunoglobin-like receptors (KIRs) that also bind to MHC-I to mediate missing-self recognition
through an analogous mechanism (Colonna and Samaridis, 1995; Long et al., 2013; Moretta et
al., 1993).
Ly49s form a family of activation and inhibitory receptors encoded by the Ly49/Klra
genes within the NK gene complex (NKC) on mouse chromosome 6 (Yokoyama and Plougastel,
2003). The inhibitory Ly49s expressed by NK cells in C57BL/6 (B6) mice are Ly49A, Ly49C,
Ly49F, Ly49G2, and Ly49I (Orr and Lanier, 2011). All of these inhibitory Ly49s have been
shown to bind to MHC-I with gene- and allele-specificity (Orr and Lanier, 2011). Importantly,
H-2Kb from B6 mice is a ligand for Ly49C and Ly49I (Hanke et al., 1999; Scarpellino et al.,
2007). In contrast, H-2Dd is a ligand for Ly49A, Ly49C, Ly49G2, and Ly49I (Hanke et al.,
1999). Ly49F promotes adhesion to target cells of the H-2d haplotype, but the exact ligand is
unknown (Hanke et al., 1999). Importantly, most ligands for Ly49s have been identified using
tetramer-binding and cell-adhesion assays with sometimes inconsistent results (Hanke et al.,
1999; Scarpellino et al., 2007). Additionally, the binding affinities and functional significance of
many of these Ly49-MHC-I interactions have not been assessed. As a result, the physiological
ligand for many inhibitory Ly49 receptors remains unclear.
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All inhibitory Ly49 receptors are thought to signal through a single cytoplasmic
immunoreceptor tyrosine-based inhibitory motif (ITIM) with the consensus sequence
(I/L/V/S)xYxx(L/V), which is the only known Ly49 signaling motif (Orr and Lanier, 2010).
Binding between Ly49s and MHC-I induces phosphorylation of the tyrosine within the Ly49
ITIM, which then recruits the phosphatases SHP-1, SHP-2, and SHIP that interfere with the
activity of kinases that function downstream of activation receptor signaling (Nakamura et al.,
1997; Olcese et al., 1996; Wang et al., 2002).
The function of Ly49 receptors was initially identified by showing that antibody blockade
of Ly49A relieved inhibition of LAK cells in vitro to promote killing of H-2Dd+ tumor cells
(Karlhofer et al., 1992). The in vivo functions of Ly49 receptors, however, are poorly
understood. Antibody depletion experiments have suggested that Ly49C/I+ NK cells reject bone
marrow that lacks H-2b and Ly49A/G2+ NK cells reject bone marrow that lacks H-2d, but these
studies are confounded because antibody depletions of Ly49 subsets reduce the total number of
NK cells and because Ly49 expression may correlate with rather than cause missing-self
recognition (Brennan et al., 1996; Sentman et al., 1989; Sun et al., 2012). Additionally, the role
of the Ly49 ITIM in effector inhibition has only been shown with a transfected rat NK cell line
and with primary NK cells from a mouse expressing an ITIM-mutant Ly49ABALB transgene
(Ly49A-Y8FBALB) (Chalifour et al., 2009; Nakamura et al., 1997). Definitive studies of Ly49s
could be performed with mice carrying targeted mutations in endogenous Ly49 genes, but
technical challenges associated with targeting a specific member of a polymorphic multigene
family have prevented the generation of Ly49 mutant mice.

1.2.3 Unexplained features of “missing-self” recognition
7

Initial studies of B2m-/- mice revealed that NK cells from MHC-I-deficient mice are
surprisingly not autoreactive as predicted by the missing-self hypothesis (Bix et al., 1991; Liao et
al., 1991). NK cells from B2m-/- mice are instead unable to reject MHC-I-deficient bone marrow
grafts in vivo and are ineffective at killing MHC-I-deficient ConA T cell blasts in vitro (Hoglund
et al., 1991; Liao et al., 1991). These findings suggest that NK cells from B2m-/- mice establish
tolerance to missing-self through unknown mechanisms. As a result, the requirements for
missing-self recognition in vivo are unclear.
NK cells from 50:50 mixed WT:B2m-/- fetal liver chimeras are also tolerant of adoptively
transferred MHC-I-deficient bone marrow and splenocytes similar to B2m-/- mice (Shifrin et al.,
2016; Wu and Raulet, 1997). Intriguingly, MCMV infection or cytokine treatment breaks
tolerance to missing-self in WT:B2m-/- chimeras, leading to a reduction in the percentage of B2m/-

cells that contribute to chimerism (Shifrin et al., 2016; Sun and Lanier, 2008a). In contrast, NK

cells from WT mice reject adoptively transferred MHC-I-deficient tumor cells and splenocytes
without pre-activation with cytokines or infection (Kärre et al., 1986; Oberg et al., 2004). As a
result, it is unclear if cytokines are only required to overcome tolerance to missing-self that
develops from chronic exposure to MHC-I-deficient cells in mixed chimeras or if cytokines are
more generally required for missing-self in vivo.

1.3 NK cell self-tolerance
1.3.1 Receptor repertoire model of NK cell tolerance
NK cells are thought to discriminate between healthy and unhealthy cells through
germline-encoded activation and inhibitory receptors (Long et al., 2013). Each NK cell expresses
a repertoire of numerous activation and inhibitory receptors that bind to a combination of host8

and pathogen-encoded ligands expressed on the surface of host cells (Long et al., 2013). As a
result, NK cells decide whether to kill or remain tolerant to a cell based on the balance of signals
through multiple receptors (Long et al., 2013). Importantly, many of these activation and
inhibitory receptors are only expressed on a fraction of NK cells in a manner that is commonly
thought to be stochastic (Raulet et al., 2001). As a consequence, NK cells form a heterogeneous
population composed of a large repertoire of related cells that express different combinations of
activation and inhibitory receptors, presumably leading to numerous specificities (Raulet et al.,
2001). Mass cytometry has been used to estimate that the human NK cell pool within an
individual is composed of 6,000 to 30,000 subpopulations based on variegated expression of
surface receptors (Horowitz et al., 2013).
T cell development in the thymus involves positive selection for T cells that recognize
self-peptide-MHC with intermediate affinity and negative selection to delete T cells that
recognize self-peptide-MHC too strongly (Xing and Hogquist, 2012). These processes are
thought to generate a repertoire of T cells that recognize self-MHC but are self-tolerant (Xing
and Hogquist, 2012). Early studies on human NK cell clones suggested that receptor repertoire
selection may also establish NK cell self-tolerance by ensuring that each NK cell expresses at
least one self-MHC-I-specific inhibitory receptor (Valiante et al., 1997). Consistent with the
receptor repertoire model of NK cell tolerance, NK cells from mice with different MHC
haplotypes express altered inhibitory Ly49 repertoires (Held et al., 1996b). Additionally, NK
cells from Ly49A transgenic mice exhibit reduced coexpression of the H-2Dd-specific receptors
Ly49A and Ly49G2 on an H-2d background, which suggests selection against NK cells that
express too many self-MHC-I-specific inhibitory receptors (Hanke et al., 1999; Held and Raulet,
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1997). However, the mechanism of receptor repertoire skewing and the role of Ly49 signaling
remain unclear.
In opposition to the receptor repertoire model of NK cell tolerance, some NK cells in WT
mice do not express any known self-MHC-I-specific inhibitory receptors but remain self-tolerant
(Fernandez et al., 2005). Additionally, although NK cells from MHC-I-deficient mice express a
skewed repertoire of inhibitory Ly49s (Salcedo et al., 1997), it is unclear how skewed receptor
expression could explain self-tolerance in the absence of a self-MHC-I ligand. As a result, it is
unlikely that the receptor repertoire development model fully explains NK cell self-tolerance
unless NK cells express unidentified receptors that recognize non-MHC self-ligands to prevent
autoreactivity.

1.3.2 NK cell education
Multiple studies have suggested that NK cells establish self-tolerance by modulating their
functionality through an “education” or “licensing” process instead of by receptor repertoire
selection (Fernandez et al., 2005; Kim et al., 2005). As mentioned previously, NK cells from
B2m-/- mice exhibit impaired in vitro killing of MHC-I-deficient ConA blasts (Liao et al., 1991),
but it is unclear if this killing defect is due to changes in the receptor repertoire or other
mechanisms because all of the relevant receptors are not known. To bypass this issue, platebound
antibody-mediated crosslinking has been used to show that NK cells from MHC-I-deficient mice
are generally hypo-responsive to stimulation through activation receptors (Fernandez et al.,
2005; Kim et al., 2005). NK cells from WT mice that lack inhibitory receptors for self-MHC-I
are also hypo-responsive to platebound antibody stimulation (Fernandez et al., 2005). These
results have been used to argue that NK cells from MHC-I-deficient mice and NK cells that lack
inhibitory receptors for self-MHC-I are self-tolerant because they are uneducated (Yokoyama
10

and Kim, 2006). However, the in vivo significance of NK cell education has not been directly
tested.
Transfer of uneducated NK cells from an MHC-I- to an MHC-I+ mouse induces
acquisition of NK cell education, and the reverse transfer induces loss of NK cell education
(Elliott et al., 2010; Joncker et al., 2010). These results have been used to argue that NK cell
education is plastic so that NK cells can become tolerant to changing MHC-I environments
(Joncker et al., 2010). Notably, however, NK cells from WT mice reject transferred MHC-Ideficient cells (Bix et al., 1991; Oberg et al., 2004) and T cells from B2m-/- mice reject
transferred WT cells, which could have impacted the outcomes of these transfer experiments
(Apasov and Sitkovsky, 1993; Glas et al., 1994; Zijlstra et al., 1992). An inducible MHC-I
transgenic mouse was used to show that NK cell education can be acquired without adoptive
transfers (Ebihara et al., 2013), but analogous studies have not been performed to test if NK cell
education is lost after MHC-I downregulation in vivo. Importantly, if NK cells adapt to a loss of
MHC-I in vivo, then it is unclear when missing-self recognition would occur.

1.3.3 Mechanisms of NK cell education
Two mechanisms have been proposed to explain NK cell education: disarming and
arming (Raulet and Vance, 2006). The disarming hypothesis proposes that self-MHC-I-specific
inhibitory Ly49s promote NK cell responsiveness indirectly by preventing overactivation of NK
cells leading to anergy (Shifrin et al., 2014). The disarming hypothesis is appealing because it
only requires Ly49 receptors to function as inhibitory receptors and because it is similar to
mechanisms of anergy and activation-induced cell death that control peripheral tolerance of T
cells (Xing and Hogquist, 2012). Additionally, chronic exposure to activation ligands in
transgenic mice can lead to NK cell hypo-responsiveness (Champsaur et al., 2010; Tripathy et
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al., 2008). It is unclear, however, whether chronic stimulation through activation ligands induces
a general or receptor-specific hypo-responsiveness (Sun and Lanier, 2008b). Additionally, it is
unclear if activation ligands are expressed at steady-state in a WT mouse although recent studies
have suggested that NKG2D and SLAM family receptor ligands may be potential candidates
(Chen et al., 2016; Thompson et al., 2017).
In contrast, the arming hypothesis proposes that binding between inhibitory Ly49s and
self-MHC-I directly promotes NK cell functionality (Yokoyama and Kim, 2006). As a result, the
arming model implies that Ly49s signal through currently unidentified pathways that differ from
the pathways required for effector inhibition. Binding between Ly49 and MHC-I in cis on the
NK cell surface has been proposed as a mechanism for arming (Bessoles et al., 2014). Studies
using transgenic mice expressing mutant Ly49A that binds to H-2Dd in trans but not in cis
suggest that unengaged Ly49A tonically suppresses NK cell function and cis binding between
Ly49A and H-2Dd relieves tonic inhibition to arm NK cells (Chalifour et al., 2009). Evidence
that Ly49A binds to H-2Dd in cis comes from studies showing that the mean fluorescence
intensity (MFI) of Ly49A is reduced in mice that express H-2Dd but elevated after acid-stripping
NK cells to destabilize surface MHC-I (Andersson et al., 2007; Doucey et al., 2004; Karlhofer et
al., 1994). However, acid-stripping only increases the MFI of Ly49A when stained with the
YE1/48 and not the JR9 monoclonal antibody even though both antibodies show a reduced MFI
in H-2Dd+ mice (Andersson et al., 2007). These results suggest that the downregulation of the
Ly49A MFI may be due to signaling-induced receptor internalization instead of or in addition to
cis binding. Additionally, it is unclear whether other Ly49s in mouse and KIRs in humans bind
to MHC-I in cis, which makes it unclear if the cis model provides definitive evidence for the
arming hypothesis. Differentiation between the arming and disarming hypotheses will require
12

identification of the activation ligands that disarm NK cells or identification of the signaling
pathways required for arming.
Notably, these models both assume that Ly49 signaling controls NK cell education.
Retroviral bone marrow chimeras and Ly49A-Y8FBALB transgenic mice that express Ly49A with
an ITIM mutation have been used to argue that Ly49 ITIM signaling is necessary for NK cell
education (Bessoles et al., 2013; Kim et al., 2005). However, definitive studies require the
generation of Ly49 mutant mice. Additionally, the downstream phosphatase SHP-1 has been
reported to be both dispensable and required for NK cell education depending on the whether a
spontaneous SHP-1 mutant or an NK cell-specific SHP-1 knockout mouse was studied (Kim et
al., 2005; Viant et al., 2014). As a result, the role of the Ly49 ITIM and downstream signaling
pathways in NK cell education remain unclear.
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Chapter 2: Immunoreceptor tyrosine-based
inhibitory motif–dependent functions of an
MHC class I-specific NK cell receptor
Published in the Proceedings of the National Academy of Sciences of the United States of
America (Bern et al., 2017).

2.1 Introduction
The functions of Ly49 receptors in vivo have been studied using retroviral bone marrow
chimeras and Ly49A transgenic mice (Chalifour et al., 2009; Kim et al., 2005). However, these
experiments, particularly with Ly49 transgenic mice, carry the caveats that the site of transgene
insertion is unknown, transgenic Ly49 is expressed at non-physiological levels and times during
NK cell development, and on cells other than NK cells. As a result of these caveats, one Ly49A
transgenic line has been shown to exhibit a complete block in NK cell development (Kim et al.,
2000; Kim et al., 2006), which appears to be inconsistent with studies of WT mice. Thus, the role
of Ly49 ITIM signaling in NK cell development, effector inhibition, education, Ly49 receptor
expression, and receptor repertoire development remain incompletely understood.
Specific targeted mutations in Ly49s have been challenging to generate because the Ly49
genes are highly related and clustered in the NK gene complex (NKC), the Ly49 cluster has a
high concentration of repetitive elements (Makrigiannis et al., 2005), and the Ly49 cluster in B6
mice encodes distinct Ly49s from those in the 129-strain initially favored for embryonic stem
(ES) cell targeting. Ly49 knockout mice have been successfully generated for only Ly49Q129,
which is expressed exclusively on myeloid cells (Tai et al., 2008), and Ly49E, which is
expressed exclusively on liver tissue-resident NK cells but not conventional splenic NK cells
14

(Aust et al., 2011; Sojka et al., 2014). Another attempt with a Ly49 targeting construct led to
generation of the NKC knockdown (NKCKD) mouse that contains a concatemerized targeting
construct inserted in the NKC (Belanger et al., 2012). Although the NKCKD mouse was shown to
express reduced levels of Ly49s, results from this mouse are confounded because the NKC is
derived from the 129-strain, Ly49 expression is not completely lost, and expression of other
NKC receptors encoded near the Ly49 gene cluster are also affected by the concatemer insertion.
In this study, we generated mice with a targeted mutation in Klra1 (Ly49a) within the
C57BL/6 NKC. This “AYF” allele encoded Ly49A with a single amino acid mutation predicted
to abolish ITIM signaling that was validated. The AYF mouse allowed us to study for the first
time the effect of losing endogenous Ly49 ITIM signaling on the in vivo development and
function of primary NK cells.

2.2 Results
2.2.1 Generation of Ly49A ITIM mutant mice
To investigate the functions of Ly49A ITIM signaling in primary NK cells, we
introduced a single nucleotide mutation in exon 4 of the Klra1 gene encoding Ly49A directly in
C57BL/6 ES cells that conferred a tyrosine-to-phenylalanine mutation in the ITIM of Ly49A
(Fig. 2.1A). Southern blot analysis verified correct targeting of the Klra1 locus in 7/370 clones
(1.9%) (Fig. 2.1B), and two of these clones were found to have a normal karyotype. Correctly
targeted ES cell clones were microinjected into Albino B6 blastocysts. Mice containing the
germline-transmitted targeted allele were bred to a CMV-Cre transgenic line to remove the
neomycin resistance cassette. The resulting allele is referred to as “AYF” (Fig. 2.1A). AYF
homozygous mice were found to contain a normal percentage and number of Ly49A+ NK cells
(Fig. 2.2A-C).
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Figure 2.1: Generation of the AYF mouse. (A) The targeted Klra1 locus encoding Ly49A is
depicted before and after removal of the neomycin resistance gene by Cre recombinase. LoxP
sites are indicated as black triangles. The AYF allele contains a point mutation in exon 4
indicated as 4* that codes for Ly49AY8F with a tyrosine-to-phenylalanine mutation in the ITIM
of Ly49A. (B) Parallel bars indicate the binding sites of probes that were used to generate the
Southern blot on genomic DNA digested with PmeI and KpnI from ES cells that were
homozygous for WT Klra1 or heterozygous for the targeted allele. Bands representing the 3’ and
5’ arms are indicated. Removal of the neomycin resistance gene was confirmed by PCR.
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Figure 2.2: Ly49A expression on WT and AYF NK cells. (A) Total splenic NK cell (CD3CD19- NK1.1+ NKp46+) numbers from WT and AYF mice. (B) Percentage of splenic NK cells
that express Ly49A. (C) Absolute number of splenic Ly49A+ NK cells. (D) Representative
histogram showing Ly49A expression on NK cells. (E) Summary of the geometric MFI (gMFI)
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13 mice per group total. Data in (D-E) is representative of 3 independent experiments with 13
mice per group total. * p < 0.05; ns = not significant (Student’s t-test).
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2.2.2 ITIM signaling is required for Ly49A to inhibit NK cell killing
To test if the ITIM is required for Ly49A to inhibit killing by primary murine NK cells,
chromium release assays were performed with purified Ly49A+ LAKs from WT B6 or
homozygous AYF mice, in a manner similar to our original assays (Karlhofer et al., 1992).
Ly49A+ LAKs from WT and AYF mice exhibited similar levels of cytotoxicity towards C1498
(H-2b) target cells at high effector-to-target (E:T) ratios (Fig. 2.3A). C1498-D12 target cells that
express transfected H-2Dd were not killed by Ly49A+ LAKs from WT mice due to the inhibitory
interaction between Ly49A and H-2Dd as previously described (Karlhofer et al., 1992). In
contrast, Ly49A+ LAKs from AYF mice killed C1498-D12 targets at higher levels than WT
LAKs, at all high E:T ratios tested (Fig. 2.3B). These data indicate that ITIM signaling is
required for Ly49A to inhibit cytotoxicity by primary NK cells and that the AYF allele
functionally inactivates the Ly49A ITIM.
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Figure 2.3: The ITIM is required for Ly49A to inhibit NK cell cytotoxicity. Chromium
release assays were performed at the indicated effector-to-target (E:T) ratios using Ly49A+
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2.2.3 Mutation of the Ly49A ITIM does not affect NK cell development
To study the function of Ly49A ITIM signaling in vivo, we bred the AYF mouse to
KODO mice that lack expression of H-2Kb and H-2Db (AYF KODO) and we introduced the
ligand for Ly49A by breeding these mice to the D8 mouse that expresses an H-2Dd transgene to
generate the AYF D8 KODO mouse. Although bone marrow competition experiments with
Ly49A transgenic mice suggested that the Ly49A-H-2Dd interaction promotes NK cell
development (Lowin-Kropf and Held, 2000), we found that total NK cell number and Ly49A+
NK cell number were both unchanged between D8 KODO and AYF D8 KODO mice (Fig. 2.4AC). Furthermore, mutation of the ITIM of Ly49A did not alter the maturation profile of Ly49A+
NK cells as indicated by CD27 and CD11b expression (Fig. 2.4D-E). Thus, these data indicate
that Ly49A ITIM signaling is not required for NK cell development.
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2.2.4 NK cell licensing by Ly49A is ITIM-dependent
To investigate the role of ITIM signaling in NK cell licensing, we stimulated NK cells
from KODO, AYF KODO, D8 KODO, and AYF D8 KODO mice with plate-bound anti-NK1.1
antibody and analyzed IFN-g production, as described previously (Fernandez et al., 2005; Kim et
al., 2005). To quantify the degree of NK cell licensing by a given Ly49, a licensing ratio was
calculated as the ratio of the percentage of IFN-γ+ cells within the Ly49+ subset over the Ly49subset as previously described (Jonsson and Yokoyama, 2010). Ly49G2+ and NKG2A+ NK cells
were gated out prior to calculating the licensing ratio for Ly49A in order to eliminate the
potential confounding effects of licensing through these other receptors by H-2Dd. Ly49A+ NK
cells from the MHC-I-deficient KODO and AYF KODO mice produced little IFN-γ after
stimulation with anti-NK1.1, which corresponded to a licensing ratio of less than 1 (Fig. 2.5AB). In contrast, a large fraction of Ly49A+ NK cells from D8 KODO mice produced IFN-γ due to
licensing by Ly49A on H-2Dd, corresponding to a Ly49A licensing ratio of greater than 1 in D8
KODO mice, as previously reported (Choi et al., 2011; Kim et al., 2005). Remarkably, Ly49A+
NK cells from AYF D8 KODO mice produced dramatically lower levels of IFN-γ compared to
D8 KODO mice with a reduction in the Ly49A licensing ratio to below 1 in AYF D8 KODO
mice (Fig. 2.5A-B). Importantly, when activation receptor signaling was bypassed with PMA
and ionomycin stimulation, Ly49A+ and Ly49A- NK cells from all strains produced equivalent
levels of IFN-γ (Fig. 2.5C), verifying that Ly49A+ NK cells from AYF D8 KODO mice
remained capable of producing IFN-γ. Thus, licensing through the interaction between Ly49A
and H-2Dd is completely abolished in AYF D8 KODO mice.
To test whether licensing through other Ly49 receptors is affected by the AYF mutation,
we assessed NK cell licensing by Ly49G2 in Ly49A- NKG2A- NK cells after stimulation with
22

plate-bound anti-NK1.1 antibody. The Ly49G2 licensing ratio was elevated in D8 KODO
compared to KODO mice (Fig. 2.5D-E), indicating that Ly49G2+ NK cells were licensed by H2Dd as has been previously suggested (Sun et al., 2012). In contrast to the Ly49A licensing ratio
(Fig. 2.5A-B), the Ly49G2 licensing ratio was unchanged between D8 KODO and AYF D8
KODO mice (Fig. 2.5D-E). Ly49G2+ and Ly49G2- NK cells from all strains responded
equivalently to stimulation with PMA and ionomycin (Fig. 2.5F). Collectively, these data
indicate that mutation of the ITIM of Ly49A impairs NK cell licensing in a manner that is cellintrinsic to Ly49A-expressing cells.
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Figure 2.5: NK cell licensing by Ly49A is impaired in AYF D8 KODO mice. Splenocytes
from KODO, AYF KODO, D8 KODO, and AYF D8 KODO mice were stimulated with platebound anti-NK1.1 antibody or with PMA and ionomycin and analyzed for intracellular IFN-γ
production by NK cells (CD3- CD19- NKp46+). (A) Representative dot plots showing IFN-γ
production by Ly49G2- NKG2A- NK cells after stimulation with plate-bound anti-NK1.1
antibody. (B-C) Relative production of IFN-γ by Ly49A+ and Ly49A- cells within the Ly49G224

NKG2A- NK cell population is quantified by a licensing ratio (see Materials and Methods) for
stimulation with (B) plate-bound anti-NK1.1 or (C) PMA and ionomycin. (D) Representative dot
plots showing IFN-γ production by Ly49A- NKG2A- NK cells after stimulation with plate-bound
anti-NK1.1 antibody. (E-F) Relative production of IFN-γ by Ly49G2+ and Ly49G2- cells within
the Ly49A- NKG2A- NK cell population is quantified by a licensing ratio for stimulation with
(E) plate-bound anti-NK1.1 or (F) PMA and ionomycin. Data are representative of 4 independent
experiments with a total of 12-15 mice per group. Error bars indicate SEM. **** p < 0.0001; ns
= not significant (One-way ANOVA with Bonferroni correction).
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2.2.5 Downregulation of the Ly49A MFI by H-2Dd does not require ITIM
signaling
To determine whether ITIM signaling is required for the H-2Dd-dependent MFI shift in
Ly49A, we compared the MFI of Ly49A in KODO, AYF KODO, D8 KODO, and AYF D8
KODO mice (Fig. 2.6). The MFI of Ly49A was reduced in D8 KODO compared to KODO mice
as previously reported (Choi et al., 2011; Johansson et al., 2005). However, the MFI of Ly49A
was also significantly downregulated in AYF D8 KODO mice compared to AYF KODO mice
and we did not observe a difference in the MFI of Ly49A in D8 KODO and AYF D8 KODO
mice (Fig. 2.6). We observed a very small but reproducible reduction in the Ly49A MFI in AYF
KODO compared to KODO mice. We also observed a similar small reduction in the Ly49A MFI
on NK cells from AYF compared to WT mice (Fig. 2.2D-E), suggesting that ITIM signaling may
modulate the expression level of Ly49A in the absence of classical MHC-I molecules expressed
as self or that the Ly49A targeting strategy slightly altered Ly49A expression. Overall, these data
show that H-2Dd downregulates the MFI of Ly49A in an ITIM-independent manner, which
argues against a role for signaling-dependent internalization of Ly49A by classical MHC-I
molecules expressed as self.
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2.2.6 Ly49A ITIM signaling regulates the NK cell receptor repertoire
To determine the role of ITIM signaling in the development of the NK cell receptor
repertoire, we assessed the expression of Ly49s and NKG2A/CD94 in splenic NK cells freshly
isolated from KODO, AYF KODO, D8 KODO, and AYF D8 KODO mice (Fig. 2.7). As
previously reported in H-2d mice (Held et al., 1996b), there was a substantial reduction in
percentage of Ly49A+ cells expressing Ly49G2 in D8 KODO when compared to KODO mice.
Moreover, we observed a significant reduction in percentage of Ly49A+ cells expressing Ly49F
and Ly49I in D8 KODO mice as compared to KODO mice. Remarkably, there were substantially
elevated percentages of Ly49A+ NK cells expressing Ly49G2, Ly49F, and Ly49I in AYF D8
KODO compared to D8 KODO mice (Fig. 2.7). In contrast, we did not detect any significant
differences in the percentages of NK cells expressing these Ly49s on Ly49A- NK cells from D8
KODO and AYF D8 KODO mice (Fig. 2.8B), which suggests that these repertoire changes are
not due to off-target mutations in other Ly49 genes. Thus, these data suggest that the effect of
Ly49A ITIM signaling on the receptor repertoire is cell-intrinsic to Ly49A-expressing cells and
that ITIM signaling is required for H-2Dd-dependent skewing of the receptor repertoire on
Ly49A+ NK cells.
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2.3 Discussion
Here we describe the first knock-in mouse with a targeted mutation in a self-MHCspecific Ly49 expressed by mature NK cells. The AYF mouse expresses Ly49A with a point
mutation known to inactivate ITIM signaling in vitro, and here we show that Ly49A ITIM
signaling inhibits cytotoxicity by primary NK cells. This mouse allowed us to definitively study
the role of the ITIM in the functions and attributes of a self-MHC-specific inhibitory NK cell
receptor. To study the role of Ly49A in NK cell development and education, we bred AYF D8
KODO mice that express the ligand for Ly49A, H-2Dd, and lack all other classical MHC-I
molecules. We used AYF D8 KODO mice to show that ITIM signaling is not required for NK
cell development but is required for NK cell licensing. Moreover, we show that ITIM signaling
is not required for H-2Dd to downregulate the Ly49A MFI. In contrast, our data provide evidence
that Ly49A ITIM signaling significantly shapes the NK cell receptor repertoire.

2.4 Materials and Methods
2.4.1 Mice
C57BL/6 (B6) mice were purchased from the National Cancer Institute (Frederick, MD) and
from Charles River Laboratories (Wilmington, MA). Albino B6 mice (B6(Cg)-Tyrc-2J/J) were
purchased from The Jackson Laboratory. H-2Kb-/- H-2Db-/- double knockout (KODO) mice were
purchased from Taconic Farms. D8 transgenic mice expressing an H-2Dd-transgene were
provided by D. Marguiles (National Institute of Allergy and Infectious Diseases, Bethesda, MD).
D8 KODO mice were generated by crossing D8-transgenic mice to KODO mice. CMV-Cre mice
(Schwenk et al., 1995) backcrossed to the C57BL/6 background were provided by Marco
Colonna (Washington University, St. Louis, MO).

31

2.4.2 Development of AYF mice
BAC recombineering (Red/ET, GeneBridges) was used to subclone an 11.9 kb region of Klra1
from BAC RP23-44607 (ACO87336, Children’s Hospital Oakland Research Institute) into the
pACYC177 vector (New England Biolabs). The pACYC177 capture vector contained a 146 bp
5’ capture arm and a 301 bp 3’ capture arm. The loxP-pGK-gb2-neo-loxP selection cassette
(GeneBridges) was cloned into the NsiI site between exons 4 and 5 of the Klra1 gene. The
tyrosine at position 8 of Ly49A was replaced with phenylalanine by cloning in a 122 bp PCR
product with XhoI and Bsu36I. Primers used to generate the Ly49AY8F mutation were the
following: 5’CACTCGAGGCACCATTTGAACTGAGAACATACTTTATATATCAATCCCAAGATGAGT
GAGCAGGAGGTCACTTTTTC-3’, 5’TTTAGTCTCCTCAGGTCTCACTTGTTTCTGCAATCCTGCAGATTTATGAAATCTCACC
ATTGAAAAAG-3’. The targeting construct was electroporated into C57BL/6NTac-derived
embryonic stem (ES) cells generated in-house (Gan et al., 2014), and positive clones were
screened by Southern blot analysis. 7/370 ES cell clones were positive by Southern blot.
Karyotyping revealed that 2/7 positive clones contained a normal karyotype. Positive clones with
a normal karyotype were microinjected into Albino B6 blastocysts by the Transgenic, Knockout,
and Micro-Injection Core at Washington University. Chimeric mice were bred to Albino B6
mice, and the targeted allele from one of the two ES cell lines was germline-transmitted. Mice
containing the germline-transmitted targeted Klra1 allele were bred to C57BL/6 mice to remove
the Albino allele and subsequently to C57BL/6 mice that express a Cre transgene under the
control of the CMV promoter (CMV-Cre) (Schwenk et al., 1995) to delete the selection cassette.
The CMV-Cre transgene was removed by breeding to C57BL/6. The AYF allele was then bred
to homozygosity for all experiments. AYF mice were subsequently crossed to KODO or D8
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KODO mice to generate the AYF KODO and AYF D8 KODO strains respectively. D8 KODO
and AYF D8 KODO mice were homozygous for the D8 transgene in all experiments.

2.4.3 Antibodies and Flow Cytometry
The following antibodies and reagents were purchased from eBioscience: anti-CD3e (145-2C11),
anti-CD19 (eBio1D3), anti-NK1.1 (PK136), anti-NKp46 (29A1.4), anti-CD27 (LG.7F9), antiCD11b (M1/70), anti-Ly49D (eBio4E5), anti-Ly49E/F (CM4), anti-Ly49G2 (eBio4D11), antiLy49H (3D10), anti-Ly49I (YLI-90), anti-CD94 (18d3), anti-NKG2AB6 (16a11), anti-IFNγ
(XMG1.2), Fixable Viability Dye eFluor 506. The following antibodies and reagents were
purchased from BD Biosciences: anti-Ly49F (HBF-719), anti-Ly49G2 (4D11), streptavidin PE
(SA-PE). The following antibodies and reagents were purchased from BioLegend: anti-NK1.1
(PK136), streptavidin APC (SA-APC). Anti-Ly49I (YLI-90) was purchased from Abcam. AntiLy49A (JR9) was purified in our laboratory from hybridoma supernatants and subsequently
conjugated to biotin or FITC. The JR9 hybridoma was generously provided by Jacques Roland
(Pasteur Institute, Paris, France). Anti-Ly49C (4LO33) was purified in our laboratory from
hybridoma supernatants and subsequently conjugated to biotin. The 4LO hybridoma was
generously provided by Suzanne Lemieux (Institut National de la Recherche Scientifique-Institut
Armand-Frappier, Laval, Quebec, Canada). Anti-NK1.1 (PK136) was purified in our laboratory
from hybridoma supernatants. The PK136 hybridoma was purchased from American Type
Culture Collection (Manassas, VA). Fc receptor blocking was performed with 2.4G2 (antiFcγRII/III) hybridoma (American Type Culture Collection, Manassas, VA) culture supernatants.
Surface staining was performed on ice in staining buffer (1% BSA, 0.01% NaN3 in PBS).
Samples were collected using a FACSCanto (BD Biosceinces), and data were analyzed using
FlowJo (Tree Star, Ashland, OR).
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2.4.4 Preparation of Ly49A+ lymphokine-activated killer cells (LAKs)
Nylon-wool non-adherent splenocytes were cultured in R10 media supplemented with 800
IU/mL of IL-2. On day 6, Ly49A+ LAKs were purified by panning with the JR9 (anti-Ly49A)
antibody as previously described (Choi et al., 2011; Karlhofer et al., 1992). LAKs were
harvested for chromium release assays on day 9 or 10. LAKs were 94-97% Ly49A+ by flow
cytometry.

2.4.5 Chromium release assay
Four-hour 51Cr release assays were performed as previously described (Karlhofer et al., 1992).
Day 9 or 10 Ly49A+ LAKs were used as effectors. C1498 target cells were purchased from
American Type Culture Collection (Manassas, VA). The C1498-D12 target cell line was
generated previously by transfecting C1498 cells with H-2Dd (Karlhofer et al., 1992).

2.4.6 In vitro stimulation and intracellular cytokine staining
Splenocytes were stimulated with anti-NK1.1 (PK136) as previously described (Jonsson and
Yokoyama, 2010; Kim et al., 2005). Briefly, 24-well culture plates were coated with 500μl of
purified PK136 (1μg/mL). Plates were washed with PBS, and then 5x106 splenocytes were added
to each well in 500μl of R10 media. Splenocytes were stimulated in parallel with 0.5μg/mL PMA
(Sigma-Aldrich) and 4μg/mL ionomycin (Sigma-Aldrich). Splenocytes were incubated at 37°C
and 5% CO2 for a total of 7 hours. Brefeldin A (GolgiPlug, BD Biosciences) was added to the
cells after 1 hour. After staining surface antigens, cells were fixed and permeabilized
(Cytofix/Cytoperm; BD Biosciences) followed staining for IFN-γ. NK cells were gated as Viable
CD3- CD19- NKp46+ lymphocytes.
The licensing ratio was calculated as [(%Ly49+IFN-γ+)/(%Ly49+)]/[(%Ly49-IFNγ+)/(%Ly49-)] as previously described (Jonsson and Yokoyama, 2010). The Ly49A licensing
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ratio was calculated on Ly49G2- NKG2A- NK cells, and the Ly49G2 licensing ratio was
calculated on Ly49A- NKG2A- NK cells.
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Chapter 3: Inflammation drives natural
killer cell missing-self reactivity
Published in the Journal of Experimental Medicine (Bern et al., 2019).

3.1 Introduction
B2m-/- mice do not exhibit NK cell-mediated autoimmunity in contrast to the predictions
of the missing-self hypothesis (Kärre et al., 1986). Our lab previously proposed that NK cells
from B2m-/- mice are self-tolerant because they are uneducated (Kim et al., 2005). This
hypothesis predicts that acute downregulation of MHC-I in a mouse that contains educated NK
cells should induce NK cell autoreactivity. More recent studies, however, suggest that NK cells
become re-educated in response to changes in the MHC-I environment to maintain self-tolerance
(Elliott et al., 2010; Joncker et al., 2010). As a result, it is unclear if acute downregulation of
MHC-I induces missing-self reactivity in vivo as proposed by the missing-self hypothesis.
Here, we generated mice in which B2m could be inducibly deleted to directly study the
response of NK cells that developed in an MHC-I-sufficient setting to acute downregulation of
MHC-I in vivo. MHC-I downregulation was found to induce multiple NK cell responses besides
missing-self reactivity that depended on the context. Importantly, the inflammatory environment
in which MHC-I was downregulated was found to regulate NK cell missing-self reactivity.

3.2 Results
3.2.1 Generation of conditional B2m knockout mice
To develop a mouse in which MHC-I expression could be downregulated, we generated
floxed B2m mice. C57BL/6 embryonic stem (ES) cells were obtained with a B2m knockout first
allele with conditional potential (B2mtm1a) (Fig. 3.1A). The HEPD0673_4_D09 ES cell clone was
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verified to be correctly targeted at the B2m locus by Southern blot analysis (Fig. 3.2) and was
microinjected into Albino B6 blastocysts. Mice containing the germline-transmitted B2mtm1a
allele were subsequently bred to a FLP transgenic line to generate the floxed B2m allele (B2mfl).
To validate the B2mfl allele, floxed B2m mice were bred with CMV-Cre transgenic mice
for ubiquitous expression of Cre to induce germline deletion of B2m (B2mΔ) (Fig. 3.1A).
Splenocytes from B6 (WT) and B2mfl/fl mice both expressed surface H-2Kb and H-2Db (Fig.
3.1B). In contrast, the original germline B2m knockout (B2m-/-) and the B2mΔ/Δ mouse both
lacked surface expression of MHC-I (Fig. 3.1B). In addition, B2mΔ/Δ mice were deficient in
CD8+ T cells (Fig. 3.1C-D), consistent with impaired positive selection of cytotoxic T cells as
originally described in B2m-/- mice (Koller et al., 1990; Zijlstra et al., 1990). Furthermore,
splenocytes from B2mΔ/Δ mice were rejected after transfer into WT mice to a similar extent as
B2m-/- splenocytes, and this rejection was abrogated by depletion of NK cells with the antiNK1.1 antibody (Fig. 3.1E-F), as previously described (Oberg et al., 2004). Taken together,
these data indicate that B2mfl/fl mice express MHC-I and that Cre mediates B2m deletion
resulting in cells from B2mΔ/Δ mice that lack surface MHC-I and are targets for missing-self
recognition.
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Figure 3.1: Conditional deletion of B2m leads to loss of surface MHC-I. (A) The targeted
B2mtm1a allele is depicted before (top) and after (middle) removal of the LacZ and neomycin
resistance (neor) genes by FLP recombinase. Germline-expressed Cre recombinase was used to
generate the B2mΔ allele (bottom). (B) Representative histograms of H-2Kb and H-2Db
expression on total lymphocytes from spleens of WT, B2mfl/fl, B2m-/-, and B2mΔ/Δ mice. (C)
Representative dot plots showing the percentage of T cells (CD19- CD3+) that express CD4 or
CD8. Data in (B) and (C) are representative of 2 independent experiments with 3 mice per group.
(D) Total splenic CD8+ T cell number in WT, B2mfl/fl, B2m-/-, and B2mΔ/Δ mice (n = 6 mice per
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group). Data in (D) are combined from 2 independent experiments. (E-F) Splenocytes from WT,
B2mfl/fl, B2m-/-, and B2mΔ/Δ mice were labeled with CFSE and differentially labeled with
CellTrace Violet (CT Violet) and CellTrace Far Red (CT Far Red) as indicated. Labeled cells
were injected IV into WT recipient mice, and donor cells were recovered from spleens of
recipients after 2 days. (E) Representative dot plots showing the relative percentages of
transferred cells (CFSE+) recovered from the spleens of WT recipient mice that were depleted of
NK cells with anti-NK1.1 (right) or undepleted (middle). (F) Percent NK cell-specific rejection
of donor cells by WT recipient mice (n = 4-5 mice per group). Data in (F) are representative of 2
independent experiments with 4-5 mice per group per experiment. Statistical significance was
calculated by one-way ANOVA. Error bars indicate mean ± SEM.
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Figure 3.2: Southern blot analysis of B2mtm1a ES cells. Southern blot on genomic DNA from
B6 ES cells and three different B2mtm1a ES cell clones: HEPD0673_4_D09 (B2m-D09),
HEPD0673_4_G10 (B2m-G10), and HEPD0673_4_H09 (B2m-H09). Genomic DNA from ES
cells was digested with (A) AhdI to probe for the 3’ homology arm or (B) PmeI and EcoRV to
probe for the 5’ homology arm. The B2m-D09 ES cell clone was found to be correctly targeted at
the B2m locus. The B2m-D09 ES cell clone was used to generate the B2mtm1a mouse.
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3.2.2 NK cell missing-self reactivity is not observed after global
downregulation of MHC-I
To study the in vivo NK cell response to acute downregulation of MHC-I, floxed B2m
mice were bred to Rosa26-Cre-ERT2 (R26-Cre-ERT2) mice that express a tamoxifen-inducible
Cre in all cells. We expected that tamoxifen treatment of B2mfl/fl R26-Cre-ERT2 mice would
induce the accumulation of MHC-I-deficient cells only when NK cells were depleted.
Surprisingly, tamoxifen induced the accumulation of a substantial population of MHC-I-deficient
cells in B2mfl/fl R26-Cre-ERT2 mice even in the presence of NK cells (Fig. 3.3A-B). In addition,
depletion of NK cells with the anti-NK1.1 antibody did not lead to any observed increase in
MHC-I-deficient cells (Fig. 3.3A-B). These data suggest that global downregulation of MHC-I
does not induce overt NK cell missing-self reactivity as predicted by the missing-self hypothesis
(Kärre et al., 1986).
To investigate the reasons why NK cell reactivity was not observed after global
downregulation of MHC-I, we first used conventional assays to test whether cells from B2mfl/fl
R26-Cre-ERT2 mice fail to become targets for missing-self recognition by NK cells after
tamoxifen-treatment (Fig. 3.3C-D). B2mfl/fl, B2mfl/fl R26-Cre-ERT2, and B2mΔ/Δ mice were treated
with either tamoxifen or vehicle control (corn oil), and splenocytes from these mice were
subsequently transferred into WT recipients. NK cell-specific rejection was quantified by
calculating the relative recovery of donor cell populations normalized to NK cell-depleted
recipient mice. Remarkably, splenocytes from B2mfl/fl R26-Cre-ERT2 mice were rejected by NK
cells only when the donor mice were treated with tamoxifen (Fig. 3.3C-D). Control B2mfl/fl
splenocytes were not rejected when donor mice received tamoxifen. In contrast, B2mΔ/Δ
splenocytes were strongly rejected by NK cells regardless of whether the donor mice received
tamoxifen or corn oil. These data show that the MHC-I-deficient cells induced by tamoxifen in
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B2mfl/fl R26-Cre-ERT2 mice become targets for missing-self recognition by NK cells upon
adoptive transfer. However, NK cells in tamoxifen-treated B2mfl/fl R26-Cre-ERT2 mice appear to
remain tolerant to these potential missing-self targets.
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Figure 3.3: Global downregulation of MHC-I does not induce overt NK cell missing-self
reactivity. (A) Representative histograms showing H-2Kb expression on CD45+ lymphocytes
from peripheral blood of B2mfl/fl R26-Cre-ERT2 mice treated with tamoxifen starting on day 0.
Mice were injected IP with anti-NK1.1 antibody to deplete NK cells or with PBS control as
indicated. (B) The percentage of H-2Kb-deficient CD45+ cells that accumulate in the blood of
tamoxifen-treated B2mfl/fl R26-Cre-ERT2 mice over time (n = 4 mice per group). Similar results
to those in (A) and (B) were observed in a second experiment with 3 mice per group. (C-D)
B2mfl/fl, B2mfl/fl R26-Cre-ERT2, and B2mΔ/Δ mice were treated with tamoxifen (Tam) or vehicle
control (Veh) on days 0 through 4, and splenocytes were harvested and labeled with CFSE plus
CT Violet and CT Far Red as indicated on day 16. Labeled splenocytes were IV injected into
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WT recipients, and recovery of donor cells was analyzed after 2 days. (C) Representative dot
plots showing the relative percentages of transferred cells (CFSE+) recovered from the spleens of
WT recipient mice that were depleted of NK cells with anti-NK1.1 (right) or undepleted (left).
(D) NK cell-specific rejection of the indicated donor cells (n = 4 recipient mice; two-way
ANOVA). Results in (C) and (D) are representative of 3 independent experiments in which
donor cells were transferred on either day 14 or 16. Each symbol in (D) represents an individual
recipient mouse from one replicate. CT Far Red labeling was reversed in one of 3 replicates.
Error bars indicate mean ± SEM.
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3.2.3 NK cells adapt to global downregulation of MHC-I
A previous attempt to generate a mouse with inducible deletion of an H-2Dd transgene
driven by Mx1-Cre or CMV-Cre-ER was confounded by baseline leakiness of Cre expression
that induced NK cell tolerance to H-2Dd-deficient cells in the absence of tamoxifen (Ioannidis et
al., 2001). To test if there was similar leakiness of Cre in our B2mfl/fl R26-Cre-ERT2 mice, we
performed an in vivo cytotoxicity assay in B2mfl/fl and B2mfl/fl R26-Cre-ERT2 mice that had been
pre-treated with vehicle control or tamoxifen (Fig. 3.4A). Remarkably, NK cells from B2mfl/fl
R26-Cre-ERT2 mice treated with vehicle control robustly rejected B2mΔ/Δ splenocytes, although
to a slightly lower extent than NK cells from B2mfl/fl mice (Fig. 3.4B-C). In contrast, NK cells
from tamoxifen-treated B2mfl/fl R26-Cre-ERT2 mice were unable to reject B2mΔ/Δ splenocytes
(Fig. 3.4B-C). These results demonstrate that NK cells from B2mfl/fl R26-Cre-ERT2 mice are
initially capable of rejecting MHC-I-deficient cells; however, induced global MHC-I
downregulation results in NK cell tolerance to missing-self.
Importantly, we did not observe any changes in NK cell number after global
downregulation of MHC-I in B2mfl/fl R26-Cre-ERT2 mice (Fig. 3.5A), and we observed only
minor changes in NK cell maturation based on CD11b, CD27, and KLRG1 expression (Fig.
3.5B-C). Additionally the NK cell inhibitory receptor repertoire was relatively unchanged by
global downregulation of MHC-I besides subtle changes in expression of Ly49C, Ly49F, and
Ly49G2 (Fig. 3.5D). Thus, it seems unlikely that global downregulation of MHC-I induces NK
cell tolerance through impacting NK cell development or the receptor repertoire.
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Figure 3.4: Global downregulation of MHC-I induces loss of NK cell licensing. (A) B2mfl/fl
and B2mfl/fl R26-Cre-ERT2 mice were treated with tamoxifen (Tam) or vehicle control (Veh) on
days 0 through 4 followed by IV injection of labeled donor splenocytes, as indicated, on day 14.
Recipient spleens were harvested after 2 days to analyze donor cell recovery. (B) Representative
histograms showing the relative percentages of transferred B2mfl/fl and B2mΔ/Δ cells (CFSE+ CT
Far Redlow) recovered from the spleens of recipient mice. B2mfl/fl and B2mΔ/Δ cells were
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differentially labeled with CT Violet as indicated. (C) Summary of NK cell-specific rejection of
B2mΔ/Δ donor cells (n = 4-5 mice per group; two-way ANOVA). Data in (C) are combined from
2 independent experiments. Similar results were seen with WT and B2m-/- donor splenocytes
(CFSE+ CT Far Redhigh) that were co-transferred in these experiments. (D-G) B2mfl/fl, B2mfl/fl
R26-Cre-ERT2, and B2mΔ/Δ mice were treated with tamoxifen or vehicle control on days 0
through 4, and splenocytes were stimulated on day 14 with plate-bound anti-NK1.1 antibody or
PMA and ionomycin. (D) Representative dot plots showing percentage of NK cells (CD3- CD19NKp46+) that express Ly49C and IFN-γ after stimulation with plate-bound anti-NK1.1. (E)
Percentage of NK cells that express IFN-γ after stimulation with plate-bound anti-NK1.1 (n = 34 mice per group; one-way ANOVA). (F) Relative production of IFN-γ by Ly49C+ and Ly49CNK cells after stimulation with anti-NK1.1 is quantified by a Ly49C licensing ratio (See
Materials and Methods) (n = 3-4 mice per group; one-way ANOVA). (G) Percentage of NK cells
that express IFN-γ after stimulation with PMA and ionomycin (n = 3-4 mice per group; one-way
ANOVA). Data in (D-G) are representative of 2 independent experiments with 3-4 mice per
group. Error bars indicate mean ± SEM.

47

B

C

0

0

B2mfl/fl

****
****

50
40

20

10

40

20

30

70

**

ns

20

****
****

15

10

10

5

5

10
0

0

ns

70

0

Ly49I
ns

Ly49H
ns

CD94
ns
ns

70

70

NKG2A
ns
ns

70

50

50

50

40

40

40

40

30

30

30

30

30

20

20

20

20

20

10

10

10

10

10

0

0

0

0

0
B2mfl/fl
R26Cre-ERT2

50

40

B2mfl/fl

50

B2mfl/fl
R26Cre-ERT2

60

B2mfl/fl

60

B2mfl/fl
R26Cre-ERT2

60

B2mfl/fl
R26Cre-ERT2

****
****

15

60

B2mfl/fl

60

Ly49F

Ly49EF

50

0
Ly49G2
ns

60

30

10
0

*

70

0

ns

B2mfl/fl
R26Cre-ERT2

ns

Ly49D

20

B2mfl/fl
R26Cre-ERT2

0

40

B2mfl/fl

20

%KLRG1+

20

Ly49C

Ly49A
ns

30
% of Total NK cells

20

**

60

B2mfl/fl

D

% of Total NK cells

40

ns

**

80

60

40

B2mfl/fl
R26Cre-ERT2

B2mfl/fl

0

ns

40

CD11b+ CD27ns
ns

B2mfl/fl

1

ns

60

60

B2mfl/fl

2

80
ns

B2mfl/fl
R26Cre-ERT2

3

CD11b+ CD27+
80

80
% of Total NK cells

4
NK cells (x106)

CD11b- CD27+

ns

B2mfl/fl
R26Cre-ERT2

ns

B2mfl/fl
R26Cre-ERT2

Tam

Veh

B2mfl/fl

A

Figure 3.5: Global downregulation of MHC-I induces minor changes in NK cell surface
phenotype. B2mfl/fl and B2mfl/fl R26-Cre-ERT2 mice were treated with tamoxifen (Tam) or
vehicle control (Veh). (A) Number of splenic NK cells (CD3- CD19- NK1.1+ NKp46+) (n = 6-8
mice per group). (B) Percent of NK cells in different stages of NK cell maturation separated by
expression of CD11b and CD27 (n = 6-8 mice per group). (C) Percent of NK cells that express
the maturation marker KLRG1 (n = 6-8 mice per group). (D) Percent of NK cells that express the
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indicated surface receptor (n = 6-8 mice per group). Data are combined from 2 independent
experiments. Statistical significance was calculated by two-way ANOVA. Error bars indicate
mean ± SEM.
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Previous adoptive transfer studies have shown that WT NK cells can reset their
responsiveness to stimulation through activation receptors when placed in an MHC-I-deficient
environment (Joncker et al., 2010). To test if NK cells adapt to global loss of MHC-I, we treated
B2mfl/fl and B2mfl/fl R26-Cre-ERT2 mice with tamoxifen or vehicle control and subsequently
stimulated splenocytes with plate-bound anti-NK1.1 antibody as previously described (Jonsson
and Yokoyama, 2010; Kim et al., 2005). IFN-γ production was analyzed as a measure of NK cell
responsiveness, and a Ly49C licensing ratio was calculated to measure the preferential capacity
of Ly49C+ NK cells to respond to stimulation (See Materials and Methods). As expected, only a
small percentage of NK cells from B2mΔ/Δ mice produced IFN-γ after stimulation (Fig. 3.4D-E),
which corresponded to a Ly49C licensing ratio below 1 (Fig. 3.4D, F). By contrast, a large
fraction of control NK cells from B2mfl/fl mice produced IFN-γ after anti-NK1.1 stimulation
regardless of whether or not the mouse was pre-treated with tamoxifen (Fig. 3.4D-E).
Additionally, Ly49C+ NK cells from B2mfl/fl mice were preferentially responsive to stimulation
through NK1.1, as indicated by a Ly49C licensing ratio above 1 (Fig. 3.4D, F). These baseline
data show that NK cells from B2mΔ/Δ mice are unlicensed while NK cells from B2mfl/fl mice are
licensed as previously shown for B2m-/- and WT NK cells (Kim et al., 2005).
Remarkably, however, NK cells from tamoxifen-treated B2mfl/fl R26-Cre-ERT2 mice
exhibited reduced IFN-γ production in response to anti-NK1.1 stimulation (Fig. 3.4D-E).
Additionally, NK cells from tamoxifen-treated B2mfl/fl R26-Cre-ERT2 mice exhibited a Ly49C
licensing ratio below 1 (Fig. 3.4D, F). By contrast, control NK cells from B2mfl/fl R26-Cre-ERT2
mice pre-treated with vehicle control produced IFN-γ at levels similar to B2mfl/fl mice.
Importantly, NK cells from tamoxifen-treated B2mfl/fl R26-Cre-ERT2 mice produced IFN-γ at
levels comparable to controls in response to stimulation with PMA and ionomycin, which
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bypasses activation receptor triggering (Fig. 3.4G). These data indicate that NK cells remain
capable of producing IFN-γ after global MHC-I downregulation, but they become hyporesponsive to stimulation through activation receptors, i.e., they become unlicensed. Thus global
downregulation of MHC-I induces NK cell tolerance to missing-self through resetting NK cell
education.

3.2.4 Missing-self is observed after downregulation of MHC-I on transferred
cells
In vivo evidence for the missing-self hypothesis has relied on transferred bone marrow
(Bix et al., 1991), splenocytes (Oberg et al., 2004), and tumor cell lines (Kärre et al., 1986). To
test if downregulation of MHC-I on transferred cells results in a distinct NK cell response
compared to global downregulation of MHC-I, we adoptively transferred splenocytes from
B2mfl/fl R26-Cre-ERT2 mice into WT recipients that were subsequently treated with tamoxifen or
vehicle control (Fig. 3.6A). Remarkably, tamoxifen treatment resulted in only a small population
of H-2Kb-deficient transferred cells (Fig. 3.6B-C). However, depletion of NK cells with antiNK1.1 dramatically increased the percentage of H-2Kb-deficient transferred cells (Fig. 3.6B-C),
indicating NK cell-mediated selection for residual MHC-I+ cells with tamoxifen treatment in
mice not receiving anti-NK1.1 depletion. To further validate this interpretation, we directly
compared co-transferred B2mfl/fl R26-Cre-ERT2 splenocytes and control B2mfl/fl splenocytes after
tamoxifen treatment and found selective loss of B2mfl/fl R26-Cre-ERT2 splenocytes that was
abrogated with NK cell depletion (Fig. 3.6D-E). These data indicate that downregulation of
MHC-I on transferred cells is sufficient to induce missing-self recognition by NK cells. Because
tamoxifen did not induce overt NK cell reactivity in B2mfl/fl R26-Cre-ERT2 mice (Fig. 3.3A-B),
these results indicate that MHC-I downregulation is capable of inducing distinct NK cell
51

responses, cytotoxicity or adaptation, depending on the context, and that adoptively transferred
cells are susceptible to missing-self rejection, even if they expressed MHC-I when transferred.
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Figure 3.6: Downregulation of MHC-I on transferred cells induces missing-self
susceptibility. (A) Splenocytes from B2mfl/fl and B2mfl/fl R26-Cre-ERT2 mice were labeled with
CellTrace (CT) Far Red and differentially labeled with CT Violet and IV injected into WT
recipient mice (20x106 of each donor). Recipient mice were then treated with tamoxifen (Tam)
or vehicle control (Veh) for 5 days starting on the day of transfer. Recipient mice were injected
IP with anti-NK1.1 to deplete NK cells or with PBS control as indicated. (B) Representative
histograms showing H-2Kb expression on transferred B2mfl/fl R26-Cre-ERT2 cells (CT Far Red+
CT Violethigh) from blood of recipient mice over time. (C) Percent of transferred B2mfl/fl R2653

Cre-ERT2 cells that are H-2Kb-deficient in the blood of recipient mice over time (n = 6 mice per
group; two-way ANOVA). Asterisks in (C) indicate statistical significance between the
tamoxifen-treated groups treated with anti-NK1.1 or PBS. (D) Representative histograms
showing the relative percentages of transferred cells (CT Far Red+) recovered from the spleens of
recipient mice on day 14. B2mfl/fl (Cre-) and B2mfl/fl R26-Cre-ERT2 (Cre+) donor cells were
distinguished by CT Violet labeling as indicated. (E) Percent NK cell-specific rejection of
B2mfl/fl R26-Cre-ERT2 donor cells by WT recipient mice treated as indicated (n = 6 mice per
group; one-way ANOVA). Data in (C) and (E) are combined from 2 independent experiments.
Error bars indicate mean ± SEM.
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We hypothesized that the number of cells that downregulate MHC-I might regulate
whether NK cells adapt to or kill MHC-I-deficient cells. To test this, we bred B2mfl/fl mice to
CD4-Cre-ERT2 transgenic mice to facilitate tamoxifen-induced deletion only in CD4+ T cells
(Aghajani et al., 2012). CD4+ T cells were chosen as target cells because they constitute a
substantially smaller cell population compared to those targeted by the R26-Cre-ERT2, CD4+ T
cells have been suggested to be targets for NK cell cytotoxicity (Lu et al., 2007; Waggoner et al.,
2011), and the CD4-Cre-ERT2 does not target NK cells (Fig. 3.7D-E). Treatment of B2mfl/fl CD4Cre-ERT2 mice with tamoxifen induced a subtle but reproducible reduction in the percent of
CD4+ T cells; however, we did not observe a statistically significant reduction in CD4+ T cell
number compared to tamoxifen-treated B2mfl/fl mice (Fig. 3.7A-C). These results suggest that
downregulation of MHC-I on CD4+ T cells leads to low-level missing-self recognition,
supporting the idea that the number of cells that downregulate MHC-I may partially regulate the
NK cell response. However, the majority of CD4+ T cells that downregulated H-2Kb in response
to tamoxifen were not rejected by NK cells (Fig. 3.7D-E), suggesting that NK cells establish
tolerance to the remaining MHC-I-deficient CD4+ T cells. To test this idea, we assessed whether
B2mfl/fl CD4-Cre-ERT2 mice pre-treated with tamoxifen were capable of rejecting transferred
B2mΔ/Δ cells. B2mfl/fl CD4-Cre-ERT2 mice treated with vehicle control were able to reject B2mΔ/Δ
splenocytes to a similar degree as B2mfl/fl controls (Fig. 3.7F-G), indicating that B2mfl/fl CD4Cre-ERT2 NK cells were not tolerant to missing-self at baseline. However, tamoxifen-treatment
abrogated the ability of NK cells in B2mfl/fl CD4-Cre-ERT2 mice to reject B2mΔ/Δ splenocytes
(Fig. 3.7F-G). These results show that downregulation of MHC-I only on CD4+ T cells induces
NK cell tolerance towards missing-self.
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Figure 3.7: Minimal NK cell reactivity is observed after downregulation of MHC-I on CD4+
T cells. B2mfl/fl and B2mfl/fl CD4-Cre-ERT2 mice were treated with tamoxifen (Tam) or vehicle
control (Veh) on days 0 through 4, and spleens were harvested for flow cytometry on day 14. (A)
Representative dot plots showing the percentage of splenic T cells (CD45+ CD19- CD3+) that
express CD4 or CD8. (B) Percent of splenic T cells that express CD4 (n = 10 mice per group).
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CD19- CD3- NK1.1+ NKp46+), B cells (CD45+ CD3- CD19+), CD8+ T cells, and CD4+ T cells
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that express H-2Kb after treatment with tamoxifen (closed bars) or vehicle (open bars) (n = 10
mice per group). Data in (B-D) are combined from 3 independent experiments. (E)
Representative histograms showing H-2Kb expression on the indicated cell types. (F-G) B2mfl/fl
and B2mfl/fl CD4-Cre-ERT2 mice were treated with tamoxifen or vehicle control on days 0
through 4 followed by IV injection of labeled donor splenocytes on day 14. Recipient spleens
were harvested after 2 days to analyze donor cell recovery. (F) Representative histograms
showing the relative percentages of transferred cells (CFSE+) recovered from the spleens of
recipient mice. (G) Summary of NK cell-specific rejection of B2mΔ/Δ donor cells (n = 4-6 mice
per group). Data in (G) is combined from 2 independent experiments. Statistical significance was
calculated by two-way ANOVA. Error bars indicate mean ± SEM.
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3.2.5 NK cell tolerance to MHC-I-deficient CD4+ T cells is not due to
education
To further investigate the mechanism by which NK cells establish tolerance to MHC-Ideficient CD4+ T cells in B2mfl/fl CD4-Cre-ERT2 mice treated with tamoxifen, we stimulated
splenocytes from B2mfl/fl, B2mfl/fl CD4-Cre-ERT2, and B2mΔ/Δ mice with plate-bound anti-NK1.1.
A higher percentage of NK cells from tamoxifen-treated B2mfl/fl CD4-Cre-ERT2 mice produced
IFN-γ after anti-NK1.1 stimulation as compared to B2mΔ/Δ mice (Fig. 3.8A-B). Importantly, NK
cells from tamoxifen-treated B2mfl/fl CD4-Cre-ERT2 mice produced IFN-γ at similar levels to
B2mfl/fl mice and vehicle controls. This was accompanied by a Ly49C licensing ratio above 1 in
tamoxifen-treated B2mfl/fl CD4-Cre-ERT2 mice, indicating that NK cells remained licensed
through Ly49C (Fig. 3.8C). We did notice a subtle reduction in the Ly49C licensing ratio
comparing vehicle- and tamoxifen-treated B2mfl/fl CD4-Cre-ERT2 mice in some experiments, but
this is of unclear significance because the licensing ratio is still above 1 (Fig. 3.8C). Together
these data show that NK cells remain responsive to stimulation through activation receptors after
downregulation of MHC-I on CD4+ T cells. These results suggest that MHC-I downregulation on
CD4+ T cells does not induce the same resetting of NK cell education that was seen after global
downregulation of MHC-I. This suggests that distinct mechanisms establish NK cell tolerance to
missing-self in B2mfl/fl R26-Cre-ERT2 and B2mfl/fl CD4-Cre-ERT2 mice treated with tamoxifen.
We next tested if NK cells from tamoxifen-treated B2mfl/fl CD4-Cre-ERT2 mice establish
tolerance to MHC-I-deficient CD4+ T cells through skewing of the inhibitory receptor repertoire.
We observed similar expression of Ly49 receptors and CD94/NKG2A on NK cells from
tamoxifen-treated B2mfl/fl CD4-Cre-ERT2 mice compared to vehicle-treated or B2mfl/fl mice (Fig.
3.8D-E). Additionally, we did not observe any alterations in NK cell number or maturation based
on expression of CD11b, CD27, and KLRG1 in tamoxifen-treated B2mfl/fl CD4-Cre-ERT2 mice
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(Fig. 3.9). These data suggest that NK cell tolerance to missing-self after MHC-I downregulation
on CD4+ T cells does not result from mechanisms analogous to T cell anergy or clonal deletion,
which establish self-tolerance by rendering T cells hypo-responsive or by altering the T cell
receptor repertoire respectively (Xing and Hogquist, 2012).

59

A

B2mfl/fl

B2mfl/fl CD4-Cre-ERT2
Tam

Veh

Tam

8.6 27.1

9.36 30.9

7.18 27.4

7.13 21.1

0.799

53.1

7.46 53.8

9.65 55.3

6.68 55.5

9.97 73.9

4.2

IFN-

ns

ns

25

ns

C

***

15
10
5

** ****

2.0
1.5
1.0
0.5
0.0

0

Ly49A

Ly49EF

15

Ly49F

15

10

10

5

5

40
20

0
Ly49G2

0
Ly49H

80

0
Ly49I

80

0
CD94

80

80

40

40

40

20

20

20

20

20

0

0

0

0

0
fl/fl

B2m

B2m
CD4Cre-ERT2

40

fl/fl

40

B2mfl/fl
CD4Cre-ERT2

60

B2mfl/fl

60

B2mfl/fl
CD4Cre-ERT2

60

B2mfl/fl
CD4Cre-ERT2

60

B2mfl/fl

60

E
B2mfl/fl
+ Tam

Ly49A

Ly49C

Ly49D

Ly49EF

Ly49F

Ly49G2

Ly49H

Ly49I

CD94

NKG2A

B2mfl/fl
CD4-CreERT2
+ Tam

60

NKG2A

B2mfl/fl
CD4Cre-ERT2

20

5

B2mfl/fl

10

80

Ly49D

80
60

40

15

B2mfl/fl

Ly49C

20

0

% of Total NK cells

60

B2mfl/fl

% of Total NK cells

25

Veh Tam Veh Tam Tam

B2m

Tam

B2mfl/fl
CD4Cre-ERT2

Veh

B2mfl/fl

Veh Tam Veh Tam Tam

B2m

%IFN-

+

20

ns

ns

2.5

B2mfl/fl
CD4Cre-ERT2

B

D

Tam

30.8

Ly49C Licensing Ratio

Ly49C

Veh

B2m

Figure 3.8: NK cell responsiveness and receptor repertoire are not affected by MHC-I
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3.2.6 Robust missing-self reactivity occurs in the context of infection
Previous studies have shown that MCMV infection breaks NK cell tolerance to missingself in mixed WT:B2m-/- chimeras (Shifrin et al., 2016; Sun and Lanier, 2008a). This led us to
hypothesize that viral infection induces NK cell missing-self reactivity in response to acute
downregulation of MHC-I as well. To test this idea, B2mfl/fl CD4-Cre-ERT2 mice were treated
with tamoxifen or vehicle control and subsequently infected with Δm157 MCMV (Fig. 3.10A).
Mice were infected with Δm157 instead of WT MCMV to exclude the effects of Ly49Hmediated cytotoxicity and so that NK cells could be depleted without significantly increasing the
viral burden (Brown et al., 2001; Bubic et al., 2004; Parikh et al., 2015), which could have
confounded previous experiments with mixed chimeras (Sun and Lanier, 2008a). In the context
of NK cell depletion, CD4+ T cells from tamoxifen-treated B2mfl/fl CD4-Cre-ERT2 mice were
mostly MHC-I-deficient even in the context of infection (Fig. 3.10B). Remarkably, however, a
high percentage of CD4+ T cells in undepleted B2mfl/fl CD4-Cre-ERT2 mice treated with
tamoxifen and infected with Δm157 MCMV expressed MHC-I (Fig. 3.10B). This selection for
MHC-I-positive cells was accompanied by a reduction in the number of splenic CD4+ T cells in
tamoxifen-treated B2mfl/fl CD4-Cre-ERT2 mice infected with Δm157 MCMV compared to NK
cell-depleted mice and B2mfl/fl controls (Fig. 3.10C). These results together suggest that in the
context of Δm157 MCMV infection, NK cells robustly reject CD4+ T cells that downregulate
MHC-I.

3.2.7 Pattern recognition receptor agonist stimulation drives NK cell
reactivity towards missing-self
Previous studies have shown that cytotoxic control of MCMV requires type I interferon
and IL-12 to prime NK cells by promoting expression of perforin and granzyme B (Fehniger et
al., 2007; Parikh et al., 2015) but it is unclear if such priming plays a role in NK cell self63

tolerance. We hypothesized that NK cell missing-self reactivity in tamoxifen-treated B2mfl/fl
CD4-Cre-ERT2 mice during viral infection might be regulated by NK cell priming by
inflammatory cytokines instead of NK cell education. To test the role of inflammation in
missing-self recognition in vivo, B2mfl/fl CD4-Cre-ERT2 mice were treated with tamoxifen
followed by PBS or poly(I:C), an adjuvant that signals through the pattern recognition receptors
(PRRs) TLR3 and MDA5 to induce production of inflammatory cytokines that activate NK cells
(Akazawa et al., 2007; McCartney et al., 2009). Poly(I:C) thus mimics aspects of the
inflammatory environment induced by MCMV infection, which also triggers MyD88-dependent
responses (Krug et al., 2004). Remarkably, poly(I:C) induced rapid loss of CD4+ T cells from the
peripheral blood of B2mfl/fl CD4-Cre-ERT2 but not B2mfl/fl mice treated with tamoxifen (Fig.
3.10D-E). This rapid loss of CD4+ T cells was not observed in B2mfl/fl CD4-Cre-ERT2 mice
treated with tamoxifen and PBS control (Fig. 3.10D-E). Importantly, depletion of NK cells with
anti-NK1.1 completely abrogated the loss of CD4+ T cells induced by poly(I:C) (Fig. 3.10D-E).
These data indicate that poly(I:C) induces NK cell missing-self reactivity in tamoxifen-treated
B2mfl/fl CD4-Cre-ERT2 mice.
To test if poly(I:C) acts through potentiating missing-self recognition, expression of
MHC-I was analyzed on residual CD4+ T cells from the spleens of B2mfl/fl CD4-Cre-ERT2 mice
treated with tamoxifen and poly(I:C) (Fig. 3.10F-G). Tamoxifen induced downregulation of H2Kb on ~80% of splenic CD4+ T cells from B2mfl/fl CD4-Cre-ERT2 mice treated with tamoxifen
and PBS control. Remarkably, substantially higher percentages of CD4+ T cells from B2mfl/fl
CD4-Cre-ERT2 mice treated with tamoxifen and poly(I:C) expressed H-2Kb compared to mice
that did not receive poly(I:C) (Fig. 3.10F-G). In contrast, depletion of NK cells with anti-NK1.1
completely abrogated this effect (Fig. 3.10F-G), indicating that poly(I:C) induced an NK cell64

dependent selection for MHC-I+ cells that was accompanied by an NK cell-dependent reduction
in splenic CD4+ T cell number in B2mfl/fl CD4-Cre-ERT2 mice treated with tamoxifen and
poly(I:C) (Fig. 3.10H). These data show that poly(I:C) induces NK cell reactivity towards MHCI-deficient CD4+ T cells, indicating that a PRR agonist can regulate NK cell reactivity towards
missing-self.
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for flow cytometry as depicted in the schematic in (A). (B) The percentage of CD4+ T cells
(CD45+ CD19- CD3+ CD8- CD4+) that express H-2Kb in the spleens of mice 4 days post
infection (n = 5-8 mice per group; two-way ANOVA). (C) The number of splenic CD4+ T cells 4
days post infection (n = 5-8 mice per group; two-way ANOVA). (D-H) B2mfl/fl and B2mfl/fl CD4Cre-ERT2 mice were treated with tamoxifen or vehicle control on days 0 through 4 followed by
IP injection of poly(I:C) or PBS on days 6, 9, and 12. Mice were injected with anti-NK1.1 to
deplete NK cells or with PBS control on day -2 and every 7 days after. (D) Representative dot
plots showing CD4 and CD8 expression on peripheral blood T cells (CD45+ CD19- CD3+) on
days 0 and 14. (E) Percentage of blood T cells that express CD4 over time (n = 4-7 mice per
group). (F) Representative histogram showing H-2Kb expression on day 14 splenic CD4+ T cells
from anti-NK1.1- or PBS-treated B2mfl/fl CD4-Cre-ERT2 mice treated with tamoxifen and
poly(I:C). (G) Percentage of splenic CD4+ T cells that express H-2Kb on day 14 (n = 4-9 mice
per group; one-way ANOVA). (H) Number of splenic CD4+ T cells on day 14 (n = 4-9 mice per
group; one-way ANOVA). Data in (B), (C), (E), (G), and (H) are combined from 2 independent
experiments. Error bars indicate mean ± SEM.
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3.3 Discussion
Here we show that acute downregulation of MHC-I in vivo does not automatically lead to
NK cell-mediated rejection, as predicted by the missing-self hypothesis. Instead, acute loss of
MHC-I can result in multiple distinct NK cell responses. Global downregulation of MHC-I was
found to induce NK cell tolerance to missing-self by resetting NK cell education. In contrast,
downregulation of MHC-I on transferred cells or CD4+ T cells could trigger missing-self
recognition and cytotoxicity but this was limited to only a few cells. Additionally, CD4+ T cellspecific downregulation of MHC-I was able to induce NK cell tolerance to missing-self without
evidence of an alteration in the capacity of NK cells to be triggered through their activation
receptors. In this setting, viral infection and PRR agonist stimulation could drive robust NK cell
reactivity towards missing-self. Thus, our findings suggest that inflammation is important for
breaking NK cell self-tolerance, despite the generally accepted paradigm based on the missingself hypothesis alone.

3.3 Materials and Methods
3.3.1 Mice
C57BL/6 (B6) mice were purchased from Charles River Laboratories (Wilmington, MA). B2m-/(B6.129P2-B2mtm1Unc/J), Albino B6 (B6(Cg)-Tyrc-2J/J), Rosa26-Cre-ERT2 (B6.129Gt(ROSA)26Sortm1(cre/ERT2)Tyj/J), and CD4-Cre-ERT2 (B6(129X1)-Tg(Cd4-cre/ERT2)11Gnri/J)
mice were purchased from The Jackson Laboratory. FLPe transgenic mice (C57BL/6Tg(CAGGS-Flpe)2ARTE) were purchased from Artemis Pharmaceuticals. CMV-Cre mice
(Schwenk et al., 1995) on the B6 background were provided by Marco Colonna (Washington
University, St. Louis, MO). Mice were 8-13 weeks old at the start of experiments except mice
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used for donor splenocytes in in vivo cytotoxicity assays, which were 8-18 weeks old at the time
of transfer.

3.3.2 Development of floxed B2m mice
Three JM8A3.N1 (C57BL/6N-Atm1Brd) ES cell clones (HEPD0673_4_D09, HEPD0673_4_G10,
and HEPD0673_4_H09) carrying the targeted allele B2mtm1a(EUCOMM)Hmgu (B2mtm1a) were
purchased from the European Conditional Mouse Mutagenesis Consortium (EUCOMM). Clone
HEPD0673_4_D09 was confirmed to be correctly targeted by Southern blot analysis and was
microinjected into Albino B6 blastocysts by the Transgenic, Knockout, and Micro-Injection Core
at Washington University in St. Louis. Chimeric mice were bred to Albino B6 to identify
germline transmission by coat color. Mice containing the germline-transmitted B2mtm1a allele
were subsequently bred to FLPe transgenic mice to generate the B2mtm1c (B2mfl) allele. The
albino and FLPe alleles were removed through breeding. Mice carrying the B2mfl allele were
bred to CMV-Cre transgenic mice to generate the B2mtm1d (B2mΔ) allele with a germline-deletion
of B2m. The CMV-Cre transgene was subsequently bred out prior to experiments with B2mΔ/Δ
mice except in one replicate of the experiment in Fig. 3.1E-F, in which the B2mΔ/Δ donor cells
were heterozygous for CMV-Cre.

3.3.3 Antibodies and flow cytometry
The following were purchased from BD Biosciences: anti-Ly49G2 (4D11), anti-Ly49F (HBF719), streptavidin PE. The following were purchased from eBioscience: Fixable Viability Dye
eFluor 506, Fixable Viability Dye eFluor 780, anti-IFNγ (XMG1.2), anti-NKp46 (29A1.4), antiNK1.1 (PK136), anti-CD19 (eBio1D3), anti-CD3e (145-2C11), anti-CD11b (M1/70), anti-CD45
(30-F11), anti-CD45.1 (A20), anti-CD45.2 (104), anti-CD4 (RM4-5), anti-CD8b (eBioH3517.2), anti-CD8a (53-6.7), anti-Ly49H (3D10), anti-Ly49E/F (CM4), anti-Ly49D (eBio4E5),
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anti-Ly49G2 (eBio4D11), anti-NKG2AB6 (16a11), anti-CD94 (18d3), anti-CD27 (LG.7F9). The
following were purchased from BioLegend: streptavidin APC, anti-KLRG1 (2F1), anti-NK1.1
(PK136), anti-H-2Kb (AF6-88.5), anti-H-2Db (KH95). The following was purchased from
Abcam: anti-Ly49I (YLI-90). The following was purchased from ThermoFisher: anti-Ly49F
(HBF-719). The following was purchased from Jackson ImmunoResearch: Alexa Fluor 647conjugated Goat anti-Mouse IgGγ, Fc subclass 3 specific (anti-mouse IgG3). PK136 antibody
(anti-NK1.1) was purified in our laboratory from supernatants of the PK136 hybridoma
(American Type Culture Collection, Manassas, VA). NK cell depletion was performed by
intraperitoneal (IP) injection of 200μg of purified PK136 antibody. Mice were excluded from
analysis if PK136 injection was shown to be unsuccessful by flow cytometry for NK cells in the
blood after the first injection or in the spleen. JR9 antibody (anti-Ly49A) was purified in our
laboratory from supernatants of the JR9 hybridoma that was provided by Jacques Roland
(Pasteur Institute, Paris, France). 4LO3311 antibody (anti-Ly49C) was purified in our laboratory
from supernatants of the 4LO3311 hybridoma that was provided by Suzanne Lemieux (Institut
National de la Recherche Scientifique-Institut Armand-Frappier, Laval, Quebec, Canada). AntiLy49A and anti-Ly49C antibodies were conjugated in our laboratory to FITC or to biotin using
the EZ-Link Sulfo-NHS-LC-LC-biotin kit (Thermo Fisher). Ly49C staining was performed with
either anti-Ly49C-biotin followed by fluorophore-conjugated streptavidin or purified anti-Ly49C
followed by anti-mouse IgG3-Alexa Fluor 647. Blocking of Fc receptors was performed with
supernatants of the 2.4G2 (anti-FcγRII/III) hybridoma (American Type Culture Collection,
Manassas, VA). Surface staining for flow cytometry was performed on ice in either 2.4G2
supernatant or staining buffer (PBS with 1% BSA and 0.01% Sodium Azide). Cells were gated
on lymphocytes with exclusion of doublets and exclusion of dead cells with Fixable Viability
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Dye (BD Biosciences) or FSC and SSC (only in some in vivo cytotoxicity experiments). CD45+
cells throughout the text refers to cells stained with either the anti-CD45 or anti-CD45.2
antibody. CD8+ cells throughout the text refers to cells stained with either the anti-CD8a or antiCD8b antibodies. Samples were analyzed using a FACSCanto (BD Biosciences) or a FACSAria
Fusion (BD Biosciences). Data was analyzed using FlowJo v9.9.6 or v10.4.2 (Tree Star,
Ashland, OR).

3.3.4 Tamoxifen treatment of mice
Mice were administered tamoxifen (Sigma-Aldrich) by oral gavage (4mg/day for 5 consecutive
days) in 200μl of corn oil (Sigma-Aldrich) as according to published protocols (Anastassiadis et
al., 2010). In most experiments, NK cells were depleted from a subset of mice by intraperitoneal
(IP) injection of 200μg anti-NK1.1 (PK136) antibody on day -2 and every 7 days after for the
duration of the experiment. When indicated, 100μg of poly(I:C) HMW (InvivoGen) in 0.9%
NaCl or a PBS control was administered to mice by IP injection.

3.3.5 In vivo cytotoxicity assay
Donor splenocytes were harvested and labeled in vitro with different combinations of 5(6)Carboxyfluorescein diacetate N-succinimidyl ester (CFSE; Life Technologies), CellTrace Violet
(CT Violet; Thermo Fisher Scientific), and CellTrace Far Red (CT Far Red; Thermo Fisher
Scientific). For experiments with 6 donor cell populations, all donor cells were labeled with
2.5μM CFSE, and donors were differentially labeled with CT Violet (5μM, 1μM, or 0.2μM) and
CT Far Red (1μM or 0.04μM). For experiments with 4 donor cell populations, all donor cells
were labeled with 2.5μM CFSE, and donors were differentially labeled with CT Violet (5μM or
0.2μM) and CT Far Red (1μM or 0.04μM). For experiments with 2 donor cell populations, all
donor cells were labeled with either 2.5μM CFSE or with 0.2μM CT Far Red depending on the
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experiment. The 2 donor cell populations were differentially labeled with CT Violet (5μM or
0.2μM). In some experiments, 4 donor cell populations were injected, but only 2 were displayed
in the figure for clarity. Recipient mice were injected IV with 2x106 of each donor cell except for
Fig. 3.6, in which 20x106 of each donor cell were injected. Spleens from recipient mice were
harvested 2 days after transfer of donor cells except for Fig. 3.6. NK cell-specific rejection was
calculated by gating on transferred cells and excluding dead cells either by Fixable Viability Dye
(BD Biosciences) or FSC and SSC. Rejection was quantified as %Rejection = [1(Target/Control)/(Target/Control)Average(NK-depleted)] x 100 where the target was the donor cell of
interest and the control was a WT or B2mfl/fl donor cell population depending on the experiment.
The ratio of target-to-control cells is normalized to the average ratio recovered from NK celldepleted mice to calculate rejection by NK cells.

3.3.6 In vitro splenocyte stimulations
Splenocytes were stimulated in vitro as previously described (Jonsson and Yokoyama, 2010;
Kim et al., 2005). Briefly, 5x106 splenocytes in R10 media were plated into 24-well culture
plates that that were pre-coated with anti-NK1.1 (PK136; 1μg/mL) or that contained 0.5μg/mL
PMA (Sigma-Aldrich) and 4μg/mL ionomycin (Sigma-Aldrich). Cells were incubated for a total
of 7 hours at 37°C. GolgiPlug (BD Biosciences) was added to the wells after the first hour. After
stimulation, cells were stained with fixable viability dye and subsequently with antibodies to
surface antigens. Cells were then fixed and permeabilized using the Fixation/Permeabilization
Solution Kit (BD Cytofix/Cytoperm) to stain for intracellular IFN-γ. Fixable viability dye was
used to gate on viable cells in all experiments. The Ly49C licensing ratio was calculated as
follows (Jonsson and Yokoyama, 2010): Ly49C licensing ratio = [(%Ly49C+IFNγ+)/(%Ly49C+)]/[(%Ly49C-IFN-γ+)/(%Ly49C-)].
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3.3.7 MCMV infections
Infections were performed with 5x103 PFU of Δm157 MCMV, which was previously shown to
differ from the WT1 MCMV strain by a single nucleotide (Cheng et al., 2010; Parikh et al.,
2015). Mice were infected by IP injection of salivary gland propagated virus in 200μl PBS.

3.3.8 Statistics
Statistical analysis was performed using Prism 7 (GraphPad, La Jolla, CA). P-values were
calculated using either one-way ANOVA or two-way ANOVA with Bonferroni’s multiple
comparison’s test. Asterisks indicate statistical significance as follows: **** p < 0.0001, *** p <
0.001, ** p < 0.01, * p < 0.05, ns = not significant.
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Chapter 4: Discussion
4.1 Ly49-MHC-I inhibition is not required for NK cell
development or maintenance
B2m-/- mice and Ly49A-tg mice contain normal numbers of NK cells (Held et al., 1996a;
Held and Raulet, 1997; Liao et al., 1991). In contrast, Ly49A-tg mixed chimeras suggest that
Ly49A-H-2Dd signaling promotes NK cell development (Lowin-Kropf and Held, 2000), and an
independent Ly49A-tg strain exhibits a complete block in NK cell development (Kim et al.,
2000). Here we used AYF D8 KODO mice to directly show that endogenous Ly49A ITIM
signaling is not required for development of normal numbers of NK cells or for their maturation.
These results argue that NK cell development does not involve a selection step that is analogous
to positive selection of TCRs that bind to self-MHC-I during T cell development (Xing and
Hogquist, 2012). Additionally, NK cell development and maturation were not substantially
affected by acute downregulation of MHC-I globally in tamoxifen-treated B2mfl/fl R26-Cre-ERT2
mice. These results suggest that NK cells do not require tonic interactions between Ly49s and
MHC-I for survival in contrast to CD8+ T cells which require TCR-MHC-I interactions for
survival (Tanchot et al., 1997). Because NK cell education is impaired in AYF D8 KODO mice
and in tamoxifen-treated B2mfl/fl R26-Cre-ERT2 mice, these results also separate NK cell
development from education.

4.2 Downregulation of the Ly49 MFI is not ITIMdependent
Signaling induces endocytosis of many receptors such as G-protein-coupled receptors,
which are internalized through a β-arrestin-dependent pathway (Perry and Lefkowitz, 2002).
Although the presence of self-MHC-I ligand correlates with a reduction in the MFI of Ly49A
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and Ly49C, it has been unclear whether this is due receptor internalization or epitope masking by
binding to MHC-I in cis (Andersson et al., 2007; Held et al., 1996b). Additionally, β-arrestin 2
has been shown to signal downstream of KIR2DL1 to potentially alter receptor expression (Yu et
al., 2008). The AYF D8 KODO mouse shows that Ly49A ITIM signaling is not required for H2Dd to downregulate the Ly49A MFI. Surprisingly, however, downregulation of MHC-I
expression on NK cells in tamoxifen-treated B2mfl/fl R26-Cre-ERT2 mice did not upregulate the
Ly49C MFI to the level seen in B2mΔ/Δ mice (Fig. 3.4D). As a result, these findings suggest that
the Ly49 MFI shift is not caused by ITIM signaling, but interactions between MHC-I and Ly49
may lead to long-lasting effects on Ly49 surface expression that are ITIM-independent.

4.3 Ly49 signaling controls receptor repertoire
development
Although we did not observe an effect of the Ly49-MHC-I interaction on NK cell
development, Ly49A ITIM signaling was found to control receptor repertoire development.
Ly49 ITIM signaling was previously suggested to impact receptor repertoire development by
comparing Ly49 expression on Ly49ABALB and Ly49A-Y8FBALB transgenic mice that express H2Dd (Bessoles et al., 2013). These studies, however, utilized the BALB allele of Ly49A for
which the ligand-specificity has not been as well characterized as the B6 allele studied here.
Additionally, these studies relied on comparisons between two different Ly49ABALB transgenic
lines in which the Ly49ABALB transgene was probably expressed at different levels and
incorporated at different locations in the genome. Likely as a result of these caveats, the
Ly49ABALB transgene induced an ITIM-dependent increase in the percentage of Ly49F+ NK
cells, which is opposite of the effects of Ly49AB6 transgene expression in H-2d mice (Hanke et
al., 2001) and of our findings in AYF D8 KODO mice. Here, we use the AYF D8 KODO mouse
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to show that endogenous Ly49AB6 ITIM signaling influences the inhibitory receptor repertoire in
a mouse with relatively normal expression of Ly49A.
Our results also show that the NK cell receptor repertoire subtly adjusts to acute global
downregulation of MHC-I. Interestingly, these subtle changes were not observed after
downregulation of MHC-I on CD4+ T cells. Similarly, floxed H-2Dd transgenic mice crossed to
CD4-Cre that constitutively lack H-2Dd only on T cells have been shown to exhibit a similar NK
cell receptor repertoire as mice that globally express the H-2Dd transgene (Bessoles et al., 2013).
These results along with ours suggest that MHC-I expression on specific cell types may be
important for dynamically regulating the inhibitory receptor repertoire. It remains unclear,
however, if only a subset of repertoire changes are reversible, whether this process involves
Ly49 ITIM signaling, and which cell types express MHC-I to induce repertoire skewing.
The sequential model of repertoire development proposes that NK cells stochastically
acquire Ly49 expression sequentially during development until a signaling threshold is reached
(Raulet et al., 1997). In contrast, the two-step selection model proposes that a repertoire of NK
cells develop that express stochastic combinations of Ly49s, and NK cells are selected that
express some but not too many self-MHC-I-specific Ly49 receptors in analogy to T cell
development (Raulet et al., 1997; Xing and Hogquist, 2012). The sequential model predicts that a
higher percentage of Ly49A+ NK cells from AYF D8 KODO mice should express each Ly49
receptor compared to Ly49A+ NK cells from D8 KODO mice regardless of MHC-I specificity.
According to the two-step selection model, a higher percentage of Ly49A+ NK cells from AYF
D8 KODO mice should express only the Ly49s that bind to H-2Dd. However, we observed that a
higher percentage of Ly49A+ NK cells from AYF D8 KODO mice expressed the H-2d-specific
receptors Ly49F, Ly49G2, and Ly49I but we did not observe a change in expression of the H76

2Dd-specific receptors Ly49C or Ly49D. As a result, the changes in the NK cell receptor
repertoire in AYF D8 KODO compared to D8 KODO mice are not fully explained by either the
sequential or the two-step selection model. Additionally, neither model explains the subtle
changes in the receptor repertoire that we observed after global MHC-I downregulation in
tamoxifen-treated B2mfl/fl R26-Cre-ERT2 mice. It is possible that our data suggest that the
receptor repertoire is established though some combination of the sequential and two-step
selection models or through a combination of developmental and peripheral mechanisms.
Alternatively, our results may suggest that some of the MHC-I-binding specificities attributed to
Ly49s by tetramer binding and cell-cell adhesion assays may not reflect physiologically relevant
ligands.

4.4 NK cells remain self-tolerant in the absence of global
Ly49-MHC-I inhibition
Although the missing-self hypothesis predicts that NK cells kill MHC-I-deficient self
cells, MHC-I-deficient mice do not exhibit NK cell autoreactivity (Liao et al., 1991). It is
possible, however, that NK cells remain self-tolerant in MHC-I-deficient mice because selfMHC-I-specific inhibitory Ly49s also bind to additional non-MHC-I ligands to prevent
autoreactivity. Here we mutated the Ly49A ITIM to test if a loss of all inhibitory signaling
through Ly49A would induce NK cell autoreactivity. Consistent with studies of MHC-I-deficient
mice (Liao et al., 1991), we did not observe any obvious signs of autoimmunity in AYF D8
KODO mice. These results show that NK cells can establish self-tolerance even in the absence of
inhibitory Ly49 signaling.
Although NK cells from MHC-I-deficient and AYF D8 KODO mice are self-tolerant,
NK cells from WT mice are known to reject adoptively transferred MHC-I-deficient cells
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without prior activation (Bix et al., 1991; Oberg et al., 2004). Based on these findings, we
hypothesized that acute downregulation of MHC-I in a mouse with educated NK cells would
induce missing-self reactivity. Surprisingly, however, we did not observe any overt signs of NK
cell autoreactivity after global MHC-I downregulation in B2mfl/fl R26-Cre-ERT2 mice. We did,
however, observe rejection of transferred B2mfl/fl R26-Cre-ERT2 splenocytes in tamoxifen-treated
WT recipients. Additionally, we observed a subtle rejection of CD4+ T cells in tamoxifen-treated
B2mfl/fl CD4-Cre-ERT2 mice that was restricted to a small number of cells. These results show
that NK cells exhibit a low-level ability to reject missing-self targets after acute downregulation
of MHC-I on a small number of transferred cells or CD4+ T cells. However, downregulation of
MHC-I largely induces NK cell tolerance to missing-self, similar to what is seen in B2m-/- and
AYF D8 KODO mice.
Bone marrow transfer experiments have shown that high doses of missing-self targets can
overcome NK cell-mediated rejection (Cudkowicz and Bennett, 1971; Koh et al., 2005).
Similarly, it is possible that no NK cell autoreactivity was observed after global MHC-I
downregulation because the large number of missing-self targets overwhelmed NK cell
cytotoxicty. Alternatively, the NK cell response to missing-self may differ qualitatively
depending on the dose of MHC-I-deficient cells. We favor the latter hypothesis due to the
finding that NK cell responsiveness to stimulation differs after global MHC-I downregluation
compared to MHC-I downregulation only on CD4+ T cells.

4.5 NK cell education is dynamically controlled by Ly49
signaling
Previous studies suggested that adoptively transferred WT NK cells adapt to an MHC-Ideficient environment by becoming re-educated and hypo-responsive to stimulation (Joncker et
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al., 2010). However, B2m-/- recipient mice in these studies were irradiated or depleted of T cells
to prevent rejection of MHC-I+ donor NK cells (Apasov and Sitkovsky, 1993; Glas et al., 1994;
Joncker et al., 2010; Zijlstra et al., 1992). Here we use B2mfl/fl R26-Cre-ERT2 and B2mfl/fl CD4Cre-ERT2 mice to directly test how NK cells respond to changes in the MHC-I environment
without adoptive transfers, irradiation, or T-cell-depletion, which could have confounded prior
studies. Our results show that global MHC-I downregulation induces NK cells to adapt through
becoming hypo-responsive to stimulation, similar to prior adoptive transfer experiments (Joncker
et al., 2010). In contrast, NK cells remained responsive to stimulation after downregulation of
MHC-I on only CD4+ T cells. These results show that global MHC-I downregulation leads to
resetting of NK cell responsiveness, but NK cells can remain educated in environments in which
MHC-I is downregulated on a limited number of cells, which more closely corresponds to the
environment that NK cells encounter during early stages of infection and tumorigenesis.
Previous studies have shown that mixed WT:B2m-/- fetal liver chimeras are tolerant of
B2m-/- bone marrow grafts (Wu and Raulet, 1997). These results have been used to support the
disarming model of NK cell education because a small number of MHC-I-deficient cells
dominantly induce tolerance to missing-self (Wu and Raulet, 1997; Yokoyama and Kim, 2006).
Here we show that tamoxifen-treated B2mfl/fl CD4-Cre-ERT2 mice are unable to reject MHC-Ideficient splenocytes, which also suggests that MHC-I-deficient cells dominantly induce
tolerance to missing-self. Importantly, however, NK cells from tamoxifen-treated B2mfl/fl CD4Cre-ERT2 mice remain educated. Similarly, recent studies have shown that NK cells from
WT:B2m-/- fetal liver chimeras remain responsive to stimulation despite being tolerant to
missing-self (Shifrin et al., 2016). As a result, our findings do not support the disarming model of
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NK cell education but instead argue that additional mechanisms besides education can establish
tolerance to missing-self as previously suggested (Shifrin et al., 2016).
Although many studies have shown that NK cell education correlates with expression of
self-MHC-I-specific Ly49 receptors (Fernandez et al., 2005; Kim et al., 2005), it has been
challenging to study the mechanism of education due to a lack of Ly49 mutant mice. Here we
show with the AYF mouse that Ly49 signaling is required for education and that the ITIM
mediates both effector inhibition and education. These results argue against the possibility that
Ly49s signal through an unidentified motif to educate NK cells. These results are consistent with
the disarming model of NK cell education (Raulet and Vance, 2006), but it remains possible that
distinct pathways downstream of the Ly49 ITIM mediate inhibition and education. Notably,
Ptpn6fl/fl NKp46-Cre mice that lack SHP-1 in NK cells exhibit a defect in NK cell education and
also a modest defect in NK cell maturation based on expression of CD11b and CD27 (Viant et
al., 2014). In contrast, we did not observe a defect in NK cell maturation in AYF D8 KODO
compared to D8 KODO mice despite the complete block in education through Ly49A. This
discrepancy may suggest that the effects of SHP-1-deletion in NK cells may be influenced by the
function of SHP-1 downstream of receptors other than self-MHC-I-specific Ly49s. Because our
results show that Ly49 ITIM signaling is required for education, future studies will be needed to
better characterize downstream mediators of Ly49 ITIM signaling in primary NK cells to
differentiate between the arming and disarming models. Altogether, our results show that the
Ly49-MHC-I interaction is required for acquisition and maintenance of NK cell education.

4.6 Inflammation promotes missing-self reactivity
Here we show that inflammatory stimuli induce NK cell-mediated rejection of CD4+ T
cells in tamoxifen-treated B2mfl/fl CD4-Cre-ERT2 mice. These results show that MHC-I
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downregulation in vivo can trigger missing-self reactivity but substantial missing-self reactivity
is restricted to inflammatory settings. Cytokines such as IL-12 and IFN-I have been shown to be
required for NK cell-mediated cytotoxic control of MCMV by priming NK cells to express
perforin and granzyme B (Fehniger et al., 2007; Parikh et al., 2015). Similarly, we hypothesize
that inflammation promotes missing-self reactivity through priming NK cells. This model
suggests that NK cell tolerance to missing-self in tamoxifen-treated B2mfl/fl CD4-Cre-ERT2 mice
is due to a lack of priming. These results are reminiscent of previous studies that showed that
RIP-GP mice that express the LCMV glycoprotein in pancreatic beta cells do not exhibit
autoimmune diabetes because of T cell ignorance (Ohashi et al., 1991; Oldstone et al., 1991).
Infection of RIP-GP mice with LCMV, however, primes previously ignorant T cells to trigger
autoreactivity and diabetes onset (Ohashi et al., 1991; Oldstone et al., 1991). Our results suggest
that NK cell ignorance of missing-self contributes to the lack of autoreactivity in B2m-/- mice in
addition to a lack of education.
Our findings provide an in vivo correlate to previous studies that showed that NK cells
are only weakly cytotoxic against most target cells in vitro without IL-2 culture or pre-activation
with poly(I:C) (Grimm et al., 1982; Liao et al., 1991). It remains unclear, however, why NK cells
are able to kill adoptively transferred target cells, such as MHC-I-deficient splenocytes and
mismatched bone marrow, without prior activation (Bix et al., 1991; Cudkowicz and Bennett,
1971; Oberg et al., 2004). It is possible that processing and adoptively transferring single-cell
suspensions of bone marrow or splenocytes induces sufficient inflammation in recipient mice to
prime NK cells to mediate missing-self recognition. We find this unlikely, however, because we
also observed low-level rejection of MHC-I-deficient CD4+ T cells in tamoxifen-treated B2mfl/fl
CD4-Cre-ERT2 mice, which suggests that NK cell cytotoxicity is not solely an artifact of
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adoptive transfer experiments. We find it more likely that basal inflammation is sufficient to
prime NK cells for a low level of cytotoxicity that is enough to reject the relatively small number
of adoptively transferred cells but not enough to mediate substantial autoreactivity.

4.7 Implications for NK cell immunotherapy
Inhibitory KIRs are attractive targets for tumor immunotherapy because antibody
blockade is thought to mimic missing-self recognition to induce NK cell-mediated tumor killing
(Daher and Rezvani, 2018). Our results, however, show that global MHC-I downregulation or
loss of Ly49 signaling do not induce substantial missing-self recognition. Instead, we show that
NK cells adapt to a loss of self-MHC-I because loss of inhibitory Ly49 signaling impairs NK cell
education and alters the receptor repertoire. These results likely explain why anti-KIR2D
checkpoint blockade was ineffective in treating patients with smoldering multiple myeloma, as
was previously proposed based on patient data (Carlsten et al., 2016; Grossenbacher et al., 2017).
However, our results suggest that combining anti-KIR antibodies with an inflammatory stimulus
may increase the efficacy of NK cell checkpoint blockade, as others have also proposed
(Ardolino et al., 2014; Vahlne et al., 2010)

4.8 Future directions
The AYF and floxed B2m mice provide valuable tools for studying the mechanism of NK
cell education. Our results show that Ly49 ITIM signaling is required for NK cell education, but
the downstream signaling pathways remain unclear. In the future, we will perform coimmunoprecipitation of Ly49A in LAKs from WT and AYF mice followed by mass
spectrometry to identify proteins that bind to the Ly49A ITIM in primary NK cells through a
non-biased approach. Additionally, we will breed floxed B2m mice that express various cell-
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type-specific Cre recombinases to test whether NK cells are educated by MHC-I expression on
specific cell types as has been previously proposed (Shifrin et al., 2016).
Here we have studied the response of NK cells to downregulation of H-2Kb and H-2Db,
but it remains unclear if our findings generalize to other MHC-I haplotypes. In the future we will
breed B2mfl/fl R26-Cre-ERT2 D8 KODO and B2mfl/fl CD4-Cre-ERT2 D8 KODO mice to study
how NK cells respond to acute downregulation of H-2Dd. We expect that global downregulation
of H-2Dd will lead to a loss of NK cell education, similar to what we observed with H-2Kb and
H-2Db. Additionally, we expect that downregulation of H-2Dd on CD4+ T cells will only lead to
robust missing-self recognition in the context of inflammation. If this is found, then the H-2Dd
background will allow us to test if inflammation-induced missing-self reactivity requires NK cell
education by breeding B2mfl/fl CD4-Cre-ERT2 AYF D8 KODO mice that should exhibit impaired
education through Ly49A.
Although we have hypothesized that inflammation promotes missing-self reactivity by
priming NK cells, it remains unclear if perforin and granzyme B are required for this form of
missing-self reactivity. To test this, we will breed Prf1-/- B2mfl/fl CD4-Cre-ERT2 and Gzmb-/B2mfl/fl CD4-Cre-ERT2 mice that contain germline knockouts of perforin or granzyme B
respectively. We hypothesize that inflammation will not induce NK cell-mediated rejection of
MHC-I-deficient CD4+ T cells in perforin- or granzyme B-deficient mice. Additionally, we will
test if inflammation is acting on the NK cell or the target cell by breeding B2mfl/fl Ifnar1fl/fl CD4Cre-ERT2 mice to delete IFNAR on only the target cells and B2mfl/fl Ifnar1fl/fl NKp46-Cre CD4Cre-ERT2 to delete IFNAR on both the target cells and the NK cell. We hypothesize that
inflammation will induce NK cell rejection of MHC-I-deficient CD4+ T cells in tamoxifen83

treated B2mfl/fl Ifnar1fl/fl CD4-Cre-ERT2 and B2mfl/fl NKp46-Cre CD4-Cre-ERT2 mice but not in
tamoxifen-treated B2mfl/fl Ifnar1fl/fl NKp46-Cre CD4-Cre-ERT2 mice.
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